Note: Descriptions are shown in the official language in which they were submitted.
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
METHODS AND COMPOSITIONS TO TREAT GLYCOSAMINOGLYCAN
ASSOCIATED MOLECULAR INTERACTIONS
BACKGROUND OF THE INVENTION
Glycosaminoglycans (GAGs) have been shown to be involved with the early
steps of the infectious process associated with several pathogens. For
example, it is
believed that sulfated proteoglycans are used by the infectious agents as
anchors or
adsorption moieties for invasion of the host cells. Several bacterial and
viral infectious
agents have been found to use extracellular membrane components, such as GAGs,
to
access host cells.
to Heparan sulfate and/or other sulfated GAGs have been suggested to be
involved in the infection process by certain bacteria such as Streptococcus
pyogenes
associated with acute rheumatic fever and poststreptococcal
glomerulonephritis,
Chlamydia trachomatis, Staphylococcus aureus and Pseudomonas aeruginosa
(cystic
fibrosis), Legionella pneumophila (Legionnaire's disease), Bordetella
pertussis (whooping
~s cough), and Mycoplasma pneumoniae. As one example, Streptococcus pyogenes
surfaces
bind fibronectin, laminin, fibrinogen, nonspecific immunoglobulins A and G, a2-
macroglobulin, (32-microglobulin and albumin. Bacterial components do not bind
to
epithelial or endothelial cells of the kidney but accumulate on the
proteoglycan-rich
regions that connect these cells to the underlying connective tissue. Another
example,
2o Chlamydia trachomatis, is one of the most common sexually transmitted
bacterial
pathogens in the world. Infection appears to be facilitated by binding of a
heparan
sulfate-like GAG present on the surface of chlamydia, to a heparan sulfate
receptor on
the target cell.
Certain types of viri, Herpesviridae, are believed to be associated with HSPG
25 during the infectious process. These viri appear to interact with a cells
surface
through GAGs found on the proteoglycans of the cell plasma membrane. These
GAGs
are similar to heparin. Cytomegalovirus (CMV) and Herpes simplex (HSV-1 and
HSV-2) are two of the viri which are believed to infect cells via cell surface
GAGS.
Although certain agents have been used to suppress infection of hosts by
so pathogens, there are limitations to their use. For example, the widespread
use of
-1-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
antibiotics has increasingly led to the problem of resistant pathogens whose
growth
can no longer be inhibited by known antibiotics. Thus, the appearance of mufti-
drug
resistant pathogens has prompted a search for new classes of compounds which
are
structurally and/or functionally different from existing drugs. Drugs having
new
mechanisms of action could be effective against resistant pathogens, where
conventional drugs can no longer be used.
SUMMARY OF THE INVENTION
Methods and compositions which are useful in the treatment of conditions
related to glycosaminoglycan (GAG)-associated molecular interactions are
presented
herein.
In one aspect the invention relates to methods for treating a condition
related to
a glycosaminoglycan-associated molecular interaction in a subject. The method
includes administering to the subject a therapeutically effective amount of a
therapeutic compound having the formula:
~s Q-{ Y-X+Jn (I)
wherein Y- is an anionic group at physiological pH; Q is a carrier molecule;
X+
is a cationic group; and n is an integer selected such that the
biodistribution of the
therapeutic compound for an intended target site is not prevented while
maintaining
activity of the therapeutic compound, or a pharmaceutically acceptable salt or
ester
2o thereof, such that the glycosaminoglycan-associated molecular interaction
is
modulated and the condition is treated. These methods can be used
therapeutically to
treat a subject, e.g., afflicted with a pathogen, or can be used
prophylactically in a
subject susceptible to pathogens.
In another embodiment, the therapeutic compound has at least one anionic
2s group covalently attached to a carrier molecule. In another embodiment, the
anionic
group covalently attached to the carrier molecule is a sulfonate group.
Accordingly,
the therapeutic compound can have the formula:
~3-X+J n (II)
-2-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
wherein Q is a carrier molecule; X+ is a cationic group; and n is an integer.
In
another embodiment, the anionic group is a sulfate group. Accordingly, the
therapeutic compound can have the formula:
Q--~-~3-X+jn (III)
s wherein Q is a carrier molecule; X+ is a cationic group; and n is an
integer.
Carrier molecules which can be used include carbohydrates, polymers, peptides,
peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups,
aromatic
groups and combinations thereof.
The invention also provides a method for modulating interactions between an
to infectious agent and a GAG in a subject. The method includes administering
to the
subject a therapeutically effective amount of a therapeutic compound having
the
formula:
Y_X+jn (I)
wherein Y- is an anionic group at physiological pH; Q is a Garner molecule; X+
~s is a cationic group; and n is an integer selected such that the
biodistribution of the
therapeutic compound for an intended target site is not prevented while
maintaining
activity of the therapeutic compound, or a pharmaceutically acceptable salt or
ester
thereof.
In another aspect, methods and therapeutic compositions are provided herein
2o for treating a subject afflicted with a disease, e.g., acute rheumatic
fever and
poststreptococcal glomerulonephritis, caused by infection by bacteria such as
Streptococcus pyogenes, Chlamydia trachomatis, Staphylococcus aureus,
Pseudomonas
aeruginosa, Legionella pneumophila, Bordetella pertussis, and Mycoplasma
pneumoniae, such
that the subject afflicted with the disease is treated. The methods include
2s administering to a subject a therapeutically effective amount of a
therapeutic
compound of formula (I) for treating the infection. The therapeutic compound
is not
carrageenan, pentosan polysulfate, fucoidan, dextran sulfate, heparin, heparan
sulfate
or dermatan sulfate.
In yet another aspect, the invention provides methods and therapeutic
so compositions for treating a subject afflicted with a disease caused by
infection of viri
-3-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
via such as Cytomegalovirus (CMV) and Herpes simplex (HSV-1 and HSV-2), such
that the subject afflicted with the disease is treated. The methods include
administering to a subject a therapeutically effective amount of a therapeutic
compound of formula (I) for treating the disease. The therapeutic compound is
not a
chondroitin sulfate.
In yet a further aspect a packaged pharmaceutical composition for treating a
condition related to a glycosaminoglycan-associated molecular interaction or
for
modulating a GAG-associated molecular interaction, e.g., between a GAG and an
infectious agent, is described herein. The packaged composition includes a
container
o holding a therapeutically effective amount of a pharmaceutical composition
for
treating the condition related to a glycosaminoglycan-associated molecular
interaction
in a subject. Alternatively, the packaged composition includes a container
holding a
therapeutically effective amount of a pharmaceutical composition for
modulating a
GAG-associated molecular interaction. The pharmaceutical composition includes
at
15 least one therapeutic compound having the formula:
Q-[-Y-X+~n (I)
wherein Y- is an anionic group at physiological pH; Q is a carrier molecule;
X+
is a cationic group; and n is an integer selected such that the
biodistribution of the
therapeutic compound for an intended target site is not prevented while
maintaining
2o activity of the therapeutic compound, or a pharmaceutically acceptable salt
or ester
thereof. Instructions for using the pharmaceutical composition for treatment
of the
condition related to a glycosaminoglycan-associated molecular interaction or
for
modulating the GAGassociated molecular interaction are included in the
packaged
pharmaceutical composition.
2s The invention further provides pharmaceutical compositions for treating a
condition related to a glycosaminoglycan-associated molecular interaction in a
subject.
Alternatively, the invention provides pharmaceutical compositions for
modulating a
GAG-associated molecular interaction in a subject. The pharmaceutical
compositions
include a therapeutically effective amount of a therapeutic compound of the
so invention, as described supra, and a pharmaceutically acceptable carrier.
-4-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
In further embodiments, the therapeutic compound has at least one anionic
group covalently attached to a carrier molecule. In yet another embodiment,
the
anionic group covalently attached to the carrier molecule is a sulfonate
group.
Accordingly, the therapeutic compound can have the formula:
Q--[ ~3-X+] n (II)
wherein Q is a carrier molecule; X+ is a cationic group; and n is an integer.
In
another embodiment, the anionic group is a sulfate group. Accordingly, the
therapeutic compound can have the formula:
Q---[-OSOg-X+]n (III)
wherein Q is a carrier molecule; X+ is a cationic group; and n is an integer.
BRIEF DESCRIPTION OF THE DRAWING
Figures 2-14 depict the chemical structures of compounds described in the
specification.
Figures 15-28 illustrate the efficacy of compounds of the invention in
inhibiting
~s binding of certain compounds, e.g., Rantes, IL-8, to heparin-coated wells.
The
compounds referenced in the drawings are:1) 3-amino-1-propanesulfonic acid,
sodium salt; 2) trisodium phosphonoformate; 3) methylene diphosphonic acid; 4)
trehalose octasulfate, octasodium salt; 5) traps-4-hydroxy-L-proline-4-
sulfate,
disodium salt; 6) nitrilo(methylene) triphosphonic acid; ~
poly(vinylsulfonate),
2o sodium salt (PVS501, Aldrich); 8) 3-[-2-6-methoxy-1,2,3,4-
tetrahydroisoquinolinyl)]-1-
propanesulfonic acid; 9) 3-phosphonopropanesulfonic acid, trisodium salt;10);
4,5-
dihydroxy-1,3,benzenedisulforuc acid, sodium salt;11) 3-cyclohexylamino-1-
propanesulfonic acid;12) O-phospho-L-serine; and 13) 2-thiopheneboronic acid.
DETAILED DESCRIPTION OF THE INVENTION
2s The features and other details of the invention will now be more
particularly
described with reference to the accompanying drawings and pointed out in the
claims.
It will be understood that particular embodiments described herein are shown
by way
of illustration and not as limitations of the invention. The principal
features of this
invention can be employed in various embodiments without departing from the
scope
so of the invention. All parts and percentages are by weight unless otherwise
specified.
-5-
CA 02338705 2001-O1-26
WO OO/o6133 PCT/IB99/01473
The invention provides methods and compositions which are useful in the
treatment of conditions related to glycosaminoglycan (GAG)-associated
molecular
interactions. In one embodiment, the invention provides a method for treating
a
condition related to a glycosaminoglycan-associated molecular interaction in a
subject.
The method includes administering to the subject, a therapeutically effective
amount
of a therapeutic compound having the formula:
Q-{ Y-X+]n (I)
wherein Y- is an anionic group at physiological pH; Q is a carrier molecule;
X+
is a cationic group; and n is an integer selected such that the
biodistribution of the
o therapeutic compound for an intended target site is not prevented while
maintaining
activity of the therapeutic compound, or a pharmaceutically acceptable salt of
ester
thereof. The methods of the invention can be used therapeutically to treat a
subject
afflicted by a pathogen or can be used prophylactically in a subject
susceptible to
pathogens. The methods of the invention are based, at least in part, on
inhibiting,
s eradicating, or preventing interaction between the cell membrane surface and
the
pathogen.
The language "treating a condition related to a glycosaminoglycan (GAG)-
associated molecular interaction" and "treatment of a condition related to a
glycosaminoglycan-associated molecular interaction" is intended to include
changes
2o in a condition related to a glycosaminoglycan-associated molecular
interaction, as
described infra, such that physiological symptoms in a subject can be
significantly
diminished or minimized. The language also includes control, prevention,
relief, or
inhibition of physiological symptoms or effects attributed to a disease state
associated
with glycosaminoglycan-associated molecular interactions. In one preferred
2s embodiment, the control of the glycosaminoglycan-associated molecular
interaction or
condition related thereto is such that the glycosaminoglycan-associated
molecular
interaction or condition related thereto is eradicated. In another preferred
embodiment, the control is selective such that a particular targeted
glycosaminoglycan-associated molecular interaction, e.g., with a pathogen, is
3o controlled while other cells and physiological flora which are not
detrimental to the
-6-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
subject are allowed to remain substantially uncontrolled or substantially
unaffected,
e.g., lymphocytes, red blood cells, white blood cells, platelets, growth
factors, etc.
The term "pathogen" is art recognized and is intended to include disease
producing agents, such as organisms, e.g., microorganisms, capable of causing
disease
s in a subject, e.g., a mammal, including, for example, bacteria, viruses,
prions and
fungi.
As used herein, "glycosaminoglycan (GAG)-associated molecular interaction" is
intended to include the binding of a GAG to, for example, a cell surface,
secreted, or
extracellular protein. This term also includes any subsequent results of such
protein
o binding such as, for example, delayed proteolytic degradation or denaturing,
changes
in protein conformation (which may, for example, lead to alterations of
biological
activity), or catalysis of a reaction between two different proteins bound to
the same or
different GAGs on the same or different proteoglycans. Also included is the
ability of
certain GAGs, e.g., heparin sulfate, to modulate the interaction of a protein
to another
~ s GAG, for example, FGF-2 (basic fibroblast growth factor) to its GAG cell
receptor.
Other GAGassociated molecular interactions include specific interactions
between specific compounds and factors. Non-limiting examples include
polypeptide
growth factors (e.g., FGFs1-9, PDGF, HGF, VEGF, TGF-(3, IL-3); extracellular
matrix
components (e.g., laminins, fibronectins; thrombospondins, tenascins,
collagens,
2o VonWillebrand's factor); proteases and anti-proteases (e.g., thrombin, TPA,
UPA,
clotting factors IX and X, PAI-1); cell-adhesion molecules (e.g., N-CAM, LI,
myelin-
associated glycoprotein); proteins involved in lipoprotein metabolism (e.g.,
APO-B,
APO-E, lipoprotein lipase); cell-cell adhesion molecules (e.g., N-CAM, myelin-
associated glycoprotein, selectins, pecam); angiogenin; lactoferrin; viral
proteins (e.g.,
2s proteins from HIV, herpes complex) and other compounds which bind to GAG.
The
definition is intended to include the result of the binding of these factors
to the GAG.
For example, the binding of polypeptide growth factor to a GAG can result in
cell
proliferation, angiogenesis, inflammation, cancer, and other biologically
important
responses.
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Also, the term "glycosaminoglycan (GAG)-associated molecular interaction"
includes microbial "interactions" with GAGs which may, for example, lead to
invasion
of a host cell by a microorganism. It includes the binding of adhesius or
other
microbial proteins to GAG and the results thereafter. Some examples of such
adhesius
are: the filamentous hemagluggtinin of Bordetella pertussis, gP120 of HIV, gpB
and
pgC of HSV, etc. It also includes interactions where the GAG functions as a
bridge
between the microbial organism and the host cell, e.g., in chlamydia
trachomatis,
heparin sulfate binds to both C. trachomatis to host cell receptors catalyzing
an
interaction between the two. Also included in the definition is any
interaction
~o between a microbial organism and a cell which is mediated through the GAG.
The term "glycosaminoglycan (GAG)-associated molecular interaction" is
further intended to include disease states or conditions caused by or
associated with
one or more pathogens which interact with extracellular membrane components,
e.g.,
glycosaminoglycans, often found on host cell surfaces. In one embodiment, the
15 disease state includes, for example, those diseases which afflict a subject
by associating
with or interfering with glycosaminoglycans found within the subject. In a
preferred
embodiment, the term "glycosaminoglycan-associated molecular interaction" does
not
include amyloidosis. In another preferred embodiment, the term
"glycosaminoglycan-
associated molecular interaction" does not include interactions between an
zo amyloidogenic protein and a constituent of basement membrane to inhibit
amyloid
deposition. In yet another preferred embodiment, the term "glycosaminoglycan"
does
not include a constituent of basement membrane, e.g., heparan sulfate
proteoglycan.
In yet another preferred embodiment, the term "glycosaminoglycan" does not
include
sulfated GAGS, e.g., heparan sulfate. Presently unknown conditions related to
2s glycosaminoglycan-associated molecular interactions that may be discovered
in the
future are encompassed, since their characterization as conditions related to
glycosaminoglycan-associated molecular interactions will be readily
determinable by
persons skilled in the art.
Conditions related to glycosaminoglycan-associated molecular interactions
3o include, for example, certain bacteria such as Streptococcus pyogenes,
associated with
-g_
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99101473
acute rheumatic fever and poststreptococcal glomerulonephritis, Chlamydia
trachomatis, Staphylococcus aureus (cystic fibrosis), Bordetella pertussis
(whooping cough)
and Mycoplasma pneumoniae. For example, Streptococcus pyogenes surfaces bind
fibronectin, laminin, fibrinogen, nonspecific immunoglobulins A and G, a2-
macroglobulin, (32-microglobulin and albumin. Infection by Chlamydia
trachomatis is
facilitated by binding of a heparan sulfate-like GAG present on the surface of
chlamydia, to a heparan sulfate receptor on the target cell.
Additionally, conditions related to glycosaminoglycan-associated molecular
interactions include certain types of viri, such as Herpesviridae, which are
believed to
o be associated with HSl?G during the infectious process. These viri appear to
interact
with a cell's surface through GAGs found on the proteoglycans of the cell
plasma
membrane. These GAGS are similar to heparin. Cytomegalovirus (CMV), HIV and
Herpes simplex (HSV-1 and HSV-2) are examples of which are believed to infect
cells
via cell surface GAGs.
In one aspect, the present invention pertains to methods for modulating a
glycosaminoglycan-associated molecular interaction, e.g., between an
infectious agent
and a GAG, in a subject. The methods include administering to the subject a
therapeutically effective amount of a therapeutic compound. The therapeutic
compound has the formula:
2o Q---~ Y-X+]n (I)
wherein Y- is an anionic group at physiological pH; Q is a carrier molecule;
X+
is a cationic group; and n is an integer selected such that the
biodistribution of the
therapeutic compound for an intended target site is not prevented while
maintaining
activity of the therapeutic compound, or a pharmaceutically acceptable salt or
ester
2s thereof.
The term "infectious agent" is intended to include those pathogens which are
associated with disease states caused by bacteria, viri or prions. The term is
also
intended to include those extracellular components, e.g., proteins, etc.,
which are
secreted, produced, or otherwise discharged by a pathogen, thereby causing the
3o subject to be afflicted with a disease state associated with the infectious
agent. Those
_9_
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
disease states associated with infectious agents include Streptococcus
pyogenes,
Chlamydia trachomatis, Staphylococcus aureus, Bordetella pertussis, Mycoplasma
pneumoniae, Herpesviridae, e.g., herpes simplex. The term infectious agent is
also
intended to encompass presently unknown infectious agents that may be
discovered
s in the future, since their characterization as a infectious agents will be
readily
determinable by persons skilled in the art.
In an embodiment, therapeutic compounds which comprise at least one sulfate
group covalently attached to a carrier molecule, or pharmaceutically
acceptable salt
thereof are used to treat a condition related to a glycosaminoglycan (GAG)-
associated
o molecular interaction or an infectious agent. In particular, the therapeutic
compounds
of the invention comprise at least one sulfate group or a functional
equivalent thereof,
for example a sulfonic acid group or other functionally equivalent anionic
group,
linked to a carrier molecule. In addition to functioning as a carrier for the
anionic
functionality, the carrier molecule can enable the compound to traverse
biological
~s membranes and to be biodistributed without excessive or premature
metabolism.
Moreover, when multiple anionic functionalities are present on a carrier
molecule, the
carrier molecule serves to space the anionic groups in a correct geometric
separation.
In one embodiment, when the condition related to a glycosaminoglycan
associated molecular interaction is associated with or caused by the bacteria
Chlamydia
2o trachomatis, the therapeutic compound is not sulfated polysaccharides kapp
and
lambda, iota carrageenans C-1263, C-3889 and C-4014, pentosan polysulfate (P-
8275),
fucodian (F-5631), dextran sulfate (D-6001), heparin (H-3393), heparan sulfate
(H-7641)
or dermatan sulfate (chondroitin sulfate A and B).
In another embodiment, when the condition related to a glycosaminoglycan-
2s associated molecular interaction is associated with or caused by
cytomegalovirus, the
therapeutic compound is not pentosan polysulfate, dextran sulfate, heparin,
copolymers of acrylic acid and vinylalcohol sulfate, a-cyclodextrin
hexasulfate and a-
cyclodextrin dodecasulfate.
-10-
CA 02338705 2001-O1-26
WO 00/06133 PCT/iB99/01473
In yet another embodiment, when the condition related to a
glycosaminoglycan-associated molecular interaction is associated with the
virus
Herpesviridae, the therapeutic agent is not chondroitin sulfate A, B or C.
In one embodiment, the method of the invention includes administering to the
subject an effective amount of a therapeutic compound which has at least one
anionic
group covalently attached to a carrier molecule. The therapeutic compound is
capable
of treating a condition related to a glycosaminoglycan-associated molecular
interaction or an infectious agent. The therapeutic compound can have the
formula:
Q--~ Y-X+]n (I)
~o wherein Y- is an anionic group at physiological pH; Q is a carrier
molecule; X+
is a cationic group; and n is an integer. The number of anionic groups ("n")
is selected
such that the biodistribution of the compound for an intended target site is
not
prevented while maintaining activity of the compound. For example, the number
of
anionic groups is not so great as to inhibit traversal of an anatomical
barrier, such as a
~ s cell membrane, or entry across a physiological barrier, such as the blood-
brain barrier,
in situations where such properties are desired. In one embodiment, n is an
integer
between 1 and 10. In another embodiment, n is an integer between 3 and 8.
An anionic group of a therapeutic compound of the invention is a negatively
charged moiety that, when attached to a carrier molecule, can inhibit an
interaction
2o between a bacteria, a virus or an infectious agent and a cell membrane. The
anionic
group is desirably negatively charged at physiological pH. Preferably, the
anionic
therapeutic compound mimics the structure of a sulfated proteoglycan, i.e., is
a
sulfated compound or a functional equivalent thereof. "Functional equivalents"
of
sulfates are intended to include compounds such as sulfamates as well as
bioisosteres.
2s Bioisosteres encompass both classical bioisosteric equivalents and non-
classical
bioisosteric equivalents. Classical and non-classical bioisosteres of sulfate
groups are
known in the art (see, e.g., Silverman, R.B. The Organic Chemistry of Drug
Design and
Drug Action, Academic Press, Inc. San Diego, CA,1992, pp.19-23). Accordingly,
a
therapeutic compound of the invention can comprise at least one anionic group
-11-
CA 02338705 2001-O1-26
WO 00/06133 .PCT/IB99/01473
including sulfonates, sulfates, sulfamates, phosphonates, phosphates,
carboxylates,
and heterocyclic groups of the following formulae:
O
O O N N
\N N
O-, O ,
~N~
Depending on the carrier molecule, more than one anionic group can be
attached thereto. When more than one anionic group is attached to a carrier
molecule,
the multiple anionic groups can be the same structural group (e.g., all
sulfonates) or,
alternatively, a combination of different anionic groups can be used (e.g.,
sulfonates
and sulfates, etc.).
A therapeutic compound of the invention typically further comprises a counter
to cation (i.e., X+ in formula (I): Q--[ Y-X+]~. Cationic groups include
positively
charged atoms and moieties. If the cationic group is hydrogen, H+, then the
compound is considered an acid, e.g., ethanesulfonic acid. If hydrogen is
replaced by
a metal or its equivalent, the compound is a salt of the acid.
Pharmaceutically
acceptable salts of the therapeutic compound are within the scope of the
invention.
~ s For example, X+ can be a pharmaceutically acceptable alkali metal,
alkaline earth,
higher valency cation (e.g., aluminum salt), polycationic counter ion or
ammonium. A
preferred pharmaceutically acceptable salt is a sodium salt but other salts
are also
contemplated within their pharmaceutically acceptable range.
Within the therapeutic compound, the anionic groups) is covalently attached
2o to a carrier molecule. Suitable carrier molecules include carbohydrates,
polymers,
peptides, peptide derivatives, aliphatic groups, alicyclic groups,
heterocyclic groups,
aromatic groups or combinations thereof. A carrier molecule can be
substituted, e.g.
with one or more amino, vitro, halogen, thiol or hydroxy groups.
As used herein, the term "carbohydrate" is intended to include substituted and
2s unsubstituted mono-, oligo-, and polysaccharides. Monosaccharides are
simple sugars
usually of the formula C6H1206 that can be combined to form oligosaccharides
or
polysaccharides. Monosaccharides include enantiomers and both the v and L
-12-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
stereoisomers of monosaccharides. Carbohydrates can have multiple anionic
groups
attached to each monosaccharide moiety. For example, in sucrose octasulfate,
four
sulfate groups are attached to each of the two monosaccharide moieties.
As used herein, the term "polymer" is intended to include molecules formed by
s the chemical union of two or more combining subunits called monomers.
Monomers
are molecules or compounds which usually contain carbon and are of relatively
low
molecular weight and simple structure. A monomer can be converted to a polymer
by
combination with itself or other similar molecules or compounds. A polymer may
be
composed of a single identical repeating subunit or multiple different
repeating
so subunits (copolymers). Polymers within the scope of this invention include
substituted and unsubstituted vinyl, acryl, styrene and carbohydrate-derived
polymers and copolymers and salts thereof. In one embodiment, the polymer has
a
molecular weight of approximately 800-1000 Daltons. Examples of polymers with
suitable covalently attached anionic groups (e.g., sulfonates or sulfates)
include
t5 poly(2-acrylamido-2-methyl-1-propanesulfonic acid); poly(2-acrylamido-2-
methyl-1-
propanesulfonic acid-co-acrylonitrile); poly(2-acrylamido-2-methyl-1-
propanesulfonic
acid- co-styrene); poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic
acid); and
sulfates and sulfonates derived from: poly(acrylic acid); poly(methyl
acrylate);
poly(methyl methacrylate); and polyvinyl alcohol); and pharmaceutically
acceptable
zo salts thereof. Examples of carbohydrate-derived polymers with suitable
covalently
attached anionic groups include those of the formula:
CH2R CH2R CH2R CH2R
RCH2-1-O -1-O -~--O -1-CHZR
CH2R
wherein R is SOg- or OS03-; and pharmaceutically acceptable salts thereof.
Peptides and peptide derivatives can also act as carrier molecules. The term
25 "peptide" includes two or more amino acids covalently attached through a
peptide
bond. Amino acids which can be used in peptide carrier molecules include those
naturally occurring amino acids found in proteins such as glycine, alanine,
valine,
cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid,
aspartic
-13-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
acid, glutamine, asparagine, lysine, arginine, proline, histidine,
phenylalanine,
tyrosine, and tryptophan. The term amino acid further includes analogs,
derivatives
and congeners of naturally occurring amino acids, one or more of which can be
present in a peptide derivative. For example, amino acid analogs can have
lengthened
s or shortened side chains or variant side chains with appropriate functional
groups.
Also included are the D and L stereoisomers of an amino acid when the
structure of
the amino acid admits of stereoisomeric forms. The term "peptide derivative"
further
includes compounds which contain molecules which mimic a peptide backbone but
are not amino acids (so-called peptidomimetics), such as benzodiazepine
molecules
io (see e.g. James, G. L. et al. (1993) Science 260:1937-1942). The anionic
groups can be
attached to a peptide or peptide derivative through a functional group on the
side
chain of certain amino acids or other suitable functional group. For example,
a sulfate
or sulfonate group can be attached through the hydroxy side chain of a serine
residue.
Accordingly, in one embodiment, the peptide comprises four amino acids and
anionic
~s groups (e.g., sulfonates) are attached to the first, second and fourth
amino acid. For
example, the peptide can be Ser-Ser-Y-Ser, wherein an anionic group is
attached to the
side chain of each serine residue and Y is any amino acid. In addition to
peptides and
peptide derivatives, single amino acids can be used as Garners in the
therapeutic
compounds of the invention. For example, cysteic acid, the sulfonate
derivative of
2o cysteine, can be used.
The term "aliphatic group" is intended to include organic compounds
characterized by straight or branched chains, typically having between 1 and
22
carbon atoms. Aliphatic groups include alkyl groups, alkenyl groups and
alkynyl
groups. In complex structures, the chains can be branched or cross-linked.
Alkyl
2s groups include saturated hydrocarbons having one or more carbon atoms,
including
straight-chain alkyl groups and branched-chain alkyl groups. Such hydrocarbon
moieties may be substituted on one or more carbons with, for example, a
halogen, a
hydroxyl, a thiol, an amino, an alkoxy, an alkylcarboxy, an alkylthio, or a
nitro group.
Unless the number of carbons is otherwise specified, "lower aliphatic" as used
herein
so means an aliphatic group, as defined above (e.g., lower alkyl, lower
alkenyl, lower
-14-
CA 02338705 2001-O1-26
WO 00/06133 PGT/IB99/01473
alkynyl), but having from one to six carbon atoms. Representative of such
lower
aliphatic groups, e.g., lower alkyl groups, are methyl, ethyl, n-propyl,
isopropyl, 2-
chloropropyl, n-butyl, sec-butyl, 2-aminobutyl, isobutyl, tert-butyl, 3-
thiopentyl, and
the like. As used herein, the term "amino" means -NH2; the term "vitro" means -
N02;
s the term "halogen" designates -F, -Cl, -Br or -I; the term "thiol" means SH;
and the term
"hydroxyl" means -OH. Thus, the term "alkylamino" as used herein means an
alkyl
group, as defined above, having an amino group attached thereto. The term
"alkylthio" refers to an alkyl group, as defined above, having a sulfhydryl
group
attached thereto. The term "alkylcarboxyl" as used herein means an alkyl
group, as
to defined above, having a carboxyl group attached thereto. The term "alkoxy"
as used
herein means an alkyl group, as defined above, having an oxygen atom, attached
thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tent-
butoxy
and the like. The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic
groups
analogous to alkyls, but which contain at least one double or triple bond
respectively.
~s The term "alicyclic group" is intended to include closed ring structures of
three
or more carbon atoms. Alicyclic groups include cycloparaffins or naphthenes
which
are saturated cyclic hydrocarbons, cycloolefins which are unsaturated with two
or
more double bonds, and cycloacetylenes which have a triple bond. They do not
include aromatic groups. Examples of cycloparaffins include cyclopropane,
2o cyclohexane, and cyclopentane. Examples of cycloolefins include
cyclopentadiene and
cyclooctatetraene. Alicyclic groups also include fused ring structures and
substituted
alicyclic groups such as alkyl substituted alicyclic groups. In the instance
of the
alicyclics such substituents can further comprise a lower alkyl, a lower
alkenyl, a
lower alkoxy, a lower alkylthio, a Iower alkylamino, a lower alkylcarboxyl, a
vitro, a
2s hydroxyl, -CF3, -CN, or the like.
The term "heterocyclic group" is intended to include closed ring structures in
which one or more of the atoms in the ring is an element other than carbon,
for
example, nitrogen, or oxygen. Heterocyclic groups can be saturated or
unsaturated
and heterocyclic groups such as pyrrole and furan can have aromatic character.
They
3o include fused ring structures such as quinoline and isoquinoline. Other
examples of
-15-
CA 02338705 2001-O1-26
WO 00/06133 'PCT/IB99101473
heterocyclic groups include pyridine and purine. Heterocyclic groups can also
be
substituted at one or more constituent atoms with, for example, a halogen, a
lower
alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a lower alkylamino,
a lower
alkylcarboxyl, a vitro, a hydroxyl, -CF3, -CN, or the like.
The term "aromatic group" is intended to include unsaturated cyclic
hydrocarbons containing one or more rings. Aromatic groups include 5- and 6-
membered single-ring groups which may include from zero to four heteroatoms,
for
example, benzene, pyrrole, furan, thiophene, irnidazole, oxazole, thiazole,
triazole,
pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. The
aromatic
to ring may be substituted at one or more ring positions with, for example, a
halogen, a
lower alkyl, a lower alkenyl, a lower alkoxy, a lower alkylthio, a Iower
alkylamino, a
lower alkylcarboxyl, a vitro, a hydroxyl, -CFg, -CN, or the like.
The therapeutic compound of the invention can be administered in a
pharmaceutically acceptable carrier. As used herein "pharmaceutically
acceptable
~s carrier" includes any and all solvents, dispersion media, coatings,
antibacterial and
antifungal agents, isotonic and absorption delaying agents, and the like which
are
compatible with the activity of the compound and are physiologically
acceptable to
the subject. An example of a pharmaceutically acceptable carrier is buffered
normal
saline {0.15 molar NaCI). The use of such media and agents for
pharmaceutically
2o active substances is well known in the art. Except insofar as any
conventional media
or agent is incompatible with the therapeutic compound, use thereof in the
compositions suitable for pharmaceutical administration is contemplated.
Supplementary active compounds can also be incorporated into the compositions.
In an embodiment of the method of the invention, the therapeutic compound
2s administered to the subject is comprised of at least one sulfonate group
covalently
attached to a carrier molecule, or a pharmaceutically acceptable salt thereof.
Accordingly, the therapeutic compound can have the formula:
Q-[ S03-X+]n (II)
wherein Q is a carrier molecule; X+ is a cationic group; and n is an integer.
3o Suitable carrier molecules and cationic groups are those described
hereinbefore. The
-16-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
number of sulfonate groups ("n") is selected such that the biodistribution of
the
compound for an intended target site is not prevented while maintaining
activity of
the compound as discussed earlier. In one embodiment, n is an integer between
2 and
10. In another embodiment, n is an integer between 3 and 8. As described
earlier,
therapeutic compounds with multiple sulfonate groups can have the sulfonate
groups
spaced such that the compound interacts optimally with a receptor site on the
cell
membrane.
In certain embodiments, the carrier molecule for a sulfonate(s) is a lower
aliphatic group (e.g., a Iower alkyl, lower alkenyl or lower alkynyl), a
heterocyclic
group, a disaccharide, a polymer or a peptide or peptide derivative.
Furthermore, the
carrier can be substituted, e.g. with one or more amino, rutro, halogen, thiol
or
hydroxy groups. In certain embodiments, the carrier molecule for a
sulfonate(s) is an
aromatic group.
Particularly suitable therapeutic compounds include 1,3-propanedisulfonic
~s acid, 3-amino-1-propanesulfonic acid, 3-dimethylamino-1-propanesulfonic
acid
sodium salt, 2-(3-sulfopropyl)-1,2,3,4-tetrahydro-9H pyrido[3,4-b]indole,
sodium salt,
3-(2-(6-methoxy-1,2,3,4-tetrahydroisoquinolinyl)]-1-propanesulfonic acid, 3-(2-
hydroxyethyl)amino-1-propanesulfonic acid, 3-(3-hydroxy-1-propyl)amino-1-
propanesulfonic acid, (-)3-((R)-2-hydroxy-1-propyl]amino-1-propanesulfonic
acid, 3-
20 (4-hydroxy-1-butyl)amino-1-propanesulfonic acid, 3-(5-hydroxy-1-
pentyl)amino-1-
propanesulfonic acid, 3-(6-hydroxy-1-hexyl)amino-1-propanesulfonic acid, 3-(2-
hydroxyethyl)amino-1-propanesulfonic acid, 3-(2-hydroxyethyl)amino-1-
propanesulfonic acid, 3-(2-hydroxyethyl)amino-1-propanesulfonic acid, 3-(2-
hydroxyethyl)amino-1-propanesulfonic acid, 3-hexylamino-1-propanesulfonic
acid, 3-
2s undecylamino-1-propanesulfonic acid, and 3-octadecylamino-1-propanesulfonic
acid,
and pharmaceutically acceptable salts or esters thereof.
Examples of sulfonated polymeric therapeutic compounds include poly(2-
acrylamido-2-methyl-1-propanesulfonic acid); poly(2-acrylamido-2-methyl-1-
propanesulfonic acid-co-acrylonitrile); poly(2-acrylamido-2-methyl-1-
propanesulfonic
so acid-co-styrene); poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic
acid); a
-17-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
sulfonic acid derivative of poly(acrylic acid); a sulfonic acid derivative of
poly(methyl
acrylate); a sulfonic acid derivative of poly(methyl methacrylate); and a
sulfonate
derivative of polyvinyl alcohol); and pharmaceutically acceptable salts
thereof.
A suitable sulfonated polymer is poly(vinylsulfonic acid) (PVS) or a
pharmaceutically acceptable salt thereof, preferably the sodium salt thereof.
In one
embodiment, PVS having a molecular weight of about 800-1000 Daltons is used.
PVS
may be used as a mixture of stereoisomers or as a single active isomer.
A suitable sulfonated disaccharide is a fully or partially sulfonated sucrose,
or
pharmaceutically acceptable salt thereof, such as sucrose octasulfonate. Other
to sulfonated saccharides include 5-deoxy-1,2-O-isopropylidene-a-D-
xylofuranose-5-
sulfonic acid (XXIII, shown as the sodium salt).
Suitable lower aliphatic sulfonated compounds for use in the invention include
ethanesulfonic acid; 2-aminoethanesulfonic acid (taurine); cysteic acid (3-
sulfoalanine
or a-amino-~3-sulfopropionic acid);1-propanesulfonic acid;1,2-ethanedisulfonic
acid;
~s 1,4-butanedisulfonic acid;1,5-pentanedisulfonic acid; and 4-hydroxybutane-1-
sulfonic
acid (VIII, shown as the sodium salt); and pharmaceutically acceptable salts
thereof.
Other aliphatic sulfonated compounds contemplated for use in the invention
include
1-butanesulfonic acid (XLVII, shown as the sodium salt), 2-propanesulfonic
acid
(XLIX, shown as the sodium salt), 3-pentanesulfonic acid (L, shown as the
sodium
zo salt), 4-heptanesulfonic acid (LII, shown as the sodium salt),1-
decanesulfonic acid
(XLVIII, shown as the sodium salt); and pharmaceutically acceptable salts
thereof.
Sulfonated substituted aliphatic compounds contemplated for use in the
invention
include 3-amino-1-propanesulfonic acid (XXII, shown as the sodium salt), 3-
hydroxypropanesulfonic acid sulfate (XXXV, shown as the disodium salt),1,7-
2s dihydroxy-4-heptanesulforuc acid (LIII, shown as the sodium salt); and
pharmaceutically acceptable salts thereof. Yet other sulfonated compounds
contemplated for use in the invention include 2-[(4-
pyridinyl)amido]ethanesulfonic
acid (LIV, depicted as the sodium salt), and pharmaceutically acceptable salts
thereof.
- 28 _
CA 02338705 2001-O1-26
WO 00/06133 .PCT/1B99/01473
Suitable heterocyclic sulfonated compounds include 3-(N-
morpholino)propanesulfonic acid; and tetrahydrothiophene-1,1-dioxide-3,4-
disulfonic
acid; and pharmaceutically acceptable salts thereof.
Aromatic sulfonated compounds include 1,3-benzenedisulfonic acid (XXXVI,
shown as the disodium salt), 2,5-dimethoxy-1,4-benzenedisulfonic acid
(depicted as
the disodium salt, XXXVII, or the dipotassium salt, XXXIX), 4-amino-3-hydroxy-
1-
naphthalenesulfonic acid (XLIII), 3,4-diamino-1-naphthalenesulfonic acid
(XLIV); and
pharmaceutically acceptable salts thereof.
In another embodiment of the method of the invention, the therapeutic
to compound administered to the subject is comprised of at Least one sulfate
group
covalently attached to a Garner molecule, or a pharmaceuHcaliy acceptable salt
thereof.
Accordingly, the therapeutic compound can have the formula:
Q"("..pSp3-X+jn (III)
wherein Q is a carrier molecule; X+ is a cationic group; and n is an integer.
~s Suitable carrier molecules and cationic groups are those described
hereinbefore. The
number of sulfate groups ("n") is selected such that the biodistribution of
the
compound for an intended target site is not prevented while maintaining
activity of
the compound as discussed earlier. In one embodiment, n is an integer between
1 and
10. In another embodiment, n is an integer between 3 and 8. As described
earlier,
2o therapeutic compounds with multiple sulfate groups can have the sulfate
groups
spaced such that the compound interacts optimally with a bacteria, virus or an
infectious agent or a cell membrane.
In certain embodiments, the carrier molecule for a sulfates) is a lower
aliphatic
group (e.g., a lower alkyl, lower alkenyl or lower alkynyl), an aromatic
group, a
2s disaccharide, a polymer or a peptide or peptide derivative. Furthermore,
the carrier
can be substituted, e.g. with one or more amino, nitro, halogen, thiol or
hydroxy
groups.
Examples of sulfated polymeric therapeutic compounds include poly(2-
acrylamido-2-methyl-propyl sulfuric acid); poly(2-acrylamido-2-methyl-propyl
so sulfuric acid-co-acrylonitrile); poly(2-acrylamido-2-methyl-propyl sulfuric
acid-co-
-29-
CA 02338705 2001-O1-26
WO 00/06133 .PCT/IB99/01473
styrene); poly(vinylsulfuric acid); poly(sodium 4-styrenesulfate); a sulfate
derivative
of poly(acrylic acid}; a sulfate derivative of poly(methyl acrylate}; a
sulfate derivative
of poly(methyl methacrylate); and a sulfate derivative of polyvinyl alcohol);
and
pharmaceutically acceptable salts thereof.
s A suitable sulfated polymer is poly(vinylsulfuric acid) or pharmaceutically
acceptable salt thereof. A suitable sulfated disaccharide is sucrose
octasulfate or
pharmaceutically acceptable salt thereof. Other contemplated sulfated
saccharides
include the acid form of methyl-a-D-glucopyranoside 2,3-Bisulfate (XVI),
methyl 4,6-
O-benzylidene-a-D-glucopyranoside 2,3-Bisulfate (XVII), 2,3,4,3',4'-sucrose
pentasulfate (XXXIII),1,3:4,6-di-0-benzylidene-D-mannitol 2,5-Bisulfate (XLI),
D-
mannitol 2,5-Bisulfate (XLII), 2,5-di-0-benzyl-D-mannitol tetrasulfate (XLV);
and
pharmaceutically acceptable salts thereof.
Suitable Iower aliphatic sulfated compounds for use in the invention include
ethyl sulfuric acid; 2-aminoethan-1-of sulfuric acid;1-propanol sulfuric
acid;1,2-
~s ethanediol disulfuric acid;1,3-propanediol disulfuric acid;1,4-butanediol
disulfuric
acid;1,5-pentanediol disulfuric acid; arid 1,4-butanediol monosulfuric acid;
and
pharmaceutically acceptable salts thereof. Other sulfated aliphatic compounds
contemplated for use in the invention include the acid form of I,3-
cyclohexanediol
Bisulfate (XL),1,3,5-heptanetriol trisulfate (XIX), 2-hydroxymethyl-1,3-
propanediol
2o trisulfate (XX), 2-hydroxymethyl-2-methyl-1,3-propanediol trisulfate
(XXI),1,3,5,7-
heptanetetraol tetrasulfate (XLVI),1,3,5,7,9-nonane pentasulfate (LI); and
pharmaceutically acceptable salts thereof. Other sulfated compounds
contemplated
for use in the invention include the acid form of 2-amino-2-hydroxymethyl-1,3-
propanediol trisulfate (XXIV), 2-benzyloxy-1,3-propanediol Bisulfate (XXIX), 3-
2s hydroxypropylsulfamic acid sulfate (XXX)2,2'-iminoethanol Bisulfate (XXXI),
N,N-
bis(2-hydroxyethyl)sulfamic acid Bisulfate (XXXII); and pharmaceutically
acceptable
salts thereof.
Suitable heterocyclic sulfated compounds include 3-(N-morpholino)
propanesulfuric acid; and tetrahydrothiophene-1,1-dioxide-3,4-diol disulfuric
acid;
so and pharmaceutically acceptable salts thereof.
-20-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
A further aspect of the invention includes pharmaceutical compositions for
treating conditions related to glycosaminoglycan-associated molecular
interactions,
such as those described supra. The therapeutic compounds in the methods of the
invention, as described hereinbefore, can be incorporated into a
pharmaceutical
s composition in an amount effective to treat a condition related to a
glycosaminoglycan-associated molecular interaction in a pharmaceutically
acceptable
carrier.
In another embodiment, the pharmaceutical compositions of the invention
include a therapeutic compound that has at least one sulfate group covalently
attached
~o to a carrier molecule, or a pharmaceutically acceptable salt thereof, in an
amount
sufficient to treat a condition related to a glycosaminoglycan-associated
molecular
interaction, and a pharmaceutically acceptable carrier. The therapeutic
compound can
have the following formula:
Q-.(_.pSp3 X+jn (III)
wherein Q is a carrier molecule; X+ is a cationic group; and n is an integer
selected such that the biodistribution of the compound for an intended target
site is
not prevented while maintaining activity of the compound.
The use of prodrugs which are converted in vivo to the therapeutic compounds
of the invention (see, e.g., R.B. Silverman,1992, "The Organic Chemistry of
Drug
2o Design and Drug Action", Academic Press, Chp. 8) are also to be considered
within
the scope of the present invention. Such prodrugs can be used to alter the
biodistribution (e.g., to allow compounds which would not typically cross the
blood-
brain barrier to cross the blood-brain barrier) or the pharmacokinetics of the
therapeutic compound. For example, an anionic group, e.g., a sulfate or
sulfonate,
25 can be esterified, e.g., with a methyl group or a phenyl group, to yield a
sulfate or
sulfonate ester. When the sulfate or sulfonate ester is administered to a
subject, the
ester is cleaved, enzymatically or non-enzymatically, reductively or
hydrolytically, to
reveal the anionic group. Such an ester can be cyclic, e.g., a cyclic sulfate
or sultone, or
two or more anionic moieties may be esterified through a linking group.
Exemplary
3o cyclic compounds include, for example, 2-sulfobenzoic acid (LV), propane
sultone
-21-
CA 02338705 2001-O1-26
WO 00/06133 PCT/1B99/01473
(LVI), butane sultone (LVII),1,3-butanediol cyclic sulfate (LVIII), a-chloro-a-
hydroxy-
o-toluenesulfonic acid sultone (LIX), and 6-nitronaphth-[1,8-cd)-1,2;
oxathiole 2,2-
dioxide (LX). In an embodiment, the prodrug is a cyclic sulfate or sultone. An
anionic
group can be esterified with moieties (e.g., acyloxymethyl esters) which are
cleaved to
s reveal an intermediate compound which subsequently decomposes to yield the
active
compound. In another embodiment, the prodrug is a reduced form of a sulfate or
sulfonate, e.g., a thiol, which is oxidized in vivo to the therapeutic
compound.
Furthermore, an anionic moiety can be esterified to a group which is actively
transported in vivo, or which is selectively taken up by target organs. The
ester can be
to selected to allow specific targeting of the therapeutic moieties to
particular organs, as
described below for carrier moieties.
Carrier molecules useful in the therapeutic compounds include carrier
molecules previously described, e.g. carbohydrates, polymers, peptides,
peptide
derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic
groups or
t5 combinations thereof. Suitable polymers include substituted and
unsubstituted vinyl,
acryl, styrene and carbohydrate-derived polymers and copolymers and salts
thereof.
Suitable carrier molecules include a lower alkyl group, a heterocyclic group,
a
disaccharide, a polymer or a peptide or peptide derivative.
Carrier molecules useful in the present invention may also include moieties
2o which allow the therapeutic compound to be selectively delivered to a
target organ or
organs. For example, if delivery of a therapeutic compound to the brain is
desired, the
carrier molecule may include a moiety capable of targeting the therapeutic
compound
to the brain, by either active or passive transport (a "targeting moiety").
Illustratively,
the carrier molecule may include a redox moiety, as described in, for example,
U.S.
25 Patents 4,540,564 and 5,389,623, both to Bodor. These patents disclose
drugs linked to
dihydropyridine moieties which can enter the brain, where they are oxidized to
a
charged pyridinium species which is trapped in the brain. Thus, drug
accumulates in
the brain. Exemplary pyridine/dihdropyridine compounds of the invention
include
sodium 1-{3-sulfopropyl)-1,4-dihydropyridine (LXI), sodium 2-(nicotinylamido)-
so ethanesulfonate (LXII), and 1-(3-sulfopropyl)-pyridinium betaine (LXIII).
Other
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
carrier moieties include compounds, such as amino acids or thyroxine, which
can be
passively or actively transported in vivo. An illustrative compound is
phenylalanyltaurine (LXIX), in which a taurine molecule is conjugated to a
phenylalanine (a large neutral amino acid). Such a carrier moiety can be
metabolically
s removed in vivo, or can remain intact as part of an active compound.
Structural
mimics of amino acids (and other actively transported moieties) are also
useful in the
invention (e.g.,1-(aminomethyl)-1-(sulfomethyl)-cyclohexane (LXX)). Other
exemplary amino acid mimetics include p-(sulfomethyl)phenylalanine (LXXII), p-
(1,3-
disulfoprop-2-yl)phenylalanine (LXXIII), and O-(1,3-disulfoprop-2-yl)tyrosine
~o {LXXIV). Exemplary thyroxine mimetics include compounds LXXV, LXVI, and
LXXVII. Many targeting moieties are known, and include, for example,
asialogiycoproteins (see, e.g. Wu, U.S. Patent 5,266,320) and other ligands
which are
transported into cells via receptor-mediated endocytosis (see below for
further
examples of targeting moieties which may be covalently or non-covalently bound
to a
~s carrier molecule). Furthermore, the therapeutic compounds of the invention
may bind
to bacteria, viri, infectious agents or cell membranes in the circulation and
thus be
transported to the site of action.
The targeting and prodrug strategies described above can be combined to
produce a compound that can be transported as a prodrug to a desired site of
action
2o and then unmasked to reveal an active compound. For example, the
dihydropyrine
strategy of Bodor (see supra) can be combined with a cyclic prodrug, as for
example in
the compound 2-(1-methyl-1,4-dihydronicotinyl)amidomethyl-propanesultone
(LXXI).
In one embodiment, the therapeutic compound in the pharmaceutical
compositions is a sulfonated polymer, for example poly(2-acrylamido-2-methyl-1-
25 propanesulfonic acid); poly(2-acrylamido-2-methyl-1-propanesulfonic acid-co-
acrylonitrile); poly(2-acrylamido-2-methyl-1-propanesulfonic acid-co-styrene);
poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic acid); a sulfonate
derivative of
poly(acrylic acid); a sulfonate derivative of poly(methyl acrylate); a
sulfonate
derivative of poly(methyl methacrylate); and a sulfonate derivative of
polyvinyl
so alcohol); and pharmaceutically acceptable salts thereof.
_23_
W,V'. ~'UN:tPA-MI~GNCHEN~ U5 E;-'jy_ CA 02338_705_2001-O1-26 41B692U35?-~ +49
89 '?39944.6°.
:::..: 1 111 UJ 1 I 1 ' -. ....-. ....... ....... .. ... . ~ a ~ ~/ 7
:::::.:-.'::':::::::::~.'.:':".:':::'::'::'.'.: UG Vl.l'1111L I71 1
f111t1,.'.:::.'..:::::~:::::::::::::;::>:::;::::.,;::.;:::.~:v ~ ..
:: ~: ~:o:w~.::: .:..: ~: :>:
.::...:::.:.....:.:~:::::.::..:::.:c:~::o::c::~:::.~:::._!S 1'tV. ~l,VUOGUJJI
...:::'.>»:::::::::::::.~::::::....:.:
.1~G:::'~::D:~~Ilfl::: ;>F~:I:'.:Q . : ..f~:.'..i>.. :. .: .. .: :: :: ......
>::::::.::.:::..::.::::
......... . . . . . ~~~.. .. .. . . ......... .
:.:::.:::....:....:.::-.:::.:.:: ::..:::.:::::.:.::.:.:.:.::~::::.:
::.::.::::::::.:::::.:::. :.L7 ... .... .:::::..:.::_.:::.
... ..... ... ...... ...... ..,
..::::::.::.:.:.~.~.:::::::::.~::.:.......>::.::-.:..::.: ::.~::
~~~.::..::::::,.:...
,..... ... .....~..... ..:....... .......:... ..,:.:. ..:.::.:::::. :.
:......:::.::::
Ncr-o~3PC
The therapecctic compound can also have the structure:
X
R1X.- I -(C'Yt Y'-)nC(X]'~Ft3
L
(IV)
in which G is XRz or R4, R~ and R2 arc ~;ach independently hydrogen, a
substituted or unsubstituted aliphatic group (preferably a branched or
straight-chain
aliphatic moiety having fion't 1 to 24 carbon ~ttorns in the chain; or an
unsubstituled or
substituted cyclic aliphatic moiety having from 4 to 7 carbon atoms ici the
aliplu~tic
ristg; suitable aliphatic and cyclic aliphltic groups are alkyl groups, more
preferably
lower alkyl), an aryl group, a hetero~yelic group, or a salt-forming ration;
lt3 is
hydrogen, lower alkyl, aryl, or 1 salt-forming canon; X is, independently for
each
1o occurrence, O or S; K~ is hydrogen, lower alkyl, azyl or amino; Yi and Y'-
are each
independently hydrogen, halogen (e.g., F, Cl, rir, or I), lower alkyl, anuno
(including
alkylamino, di~ulkylacnino, arylamino, diarylalnino, and alkylarylanuno),
hydroxy,
alkoxy, or aryloxy; 1nd n is 1n integer from 0 to 12 (more preferably ~ to 6,
more
preferably 0 or 1).
Suitable therapeutic COmpOOndS for use iit the it~Vention include compounds in
which both R~ and hZ are pharmaceutically acceptable salt-forming rations. Tt
will be
appreciated tl~t the stoicluontetry of an aniotuc compound to a salt-forming
courLterion (if any) will vary depending on the charge of the anionic portion
of the
zo compound (if any) a:~d the chruge of the counterion. In a particularly
suitable
embodiment, R1, R2 and R3 are elch independently a sodium, potassium or
calcium
ration. In certain embociiments in which at least one of R1 and R2 is an
aliphatic
group, the aliphatic group has between I and 10 carbons atoms in the sh night
or
branched chain, and is more preferably a lower alkyl group. In other
embodiments in
zs which at least one of R1 and R2 is an aliphatic group, the aIiphaiic group
has between
10 acrd 2~ carboais alo:ns in the stzaight or branched chain. In certain
embodiments, n
i.~ 0 or 'I; mare preferably, n is 0. In certain embodiments of the then
apeutic
compounds, Yl and Yz 1re each hydrogen.
_2.~_
pIJIEt~DED SHEf~T '
:::.:::::l~t'll_lv=~t7fl~: ;: :::
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
In certain embodiments, the therapeutic compound of the invention can have
the structure:
X
R~X~P--(CY~Y2)nC(O)OR3
~2
(V)
in which R1, R2, R3, Y1, Y2, X and n are as defined above. In other
embodiments, the therapeutic compound of the invention can have the structure:
X
I I
RIO~P'-(CYtYz)nCH~RaRb)C(O)OR3
OR2
in which R1, R2, R3, Y~, Y2, and X are as defined above, Ra and Rb are each
independently hydrogen, alkyl, aryl, or heterocyclyl, or Ra and Rb, taken
together
with the nitrogen atom to which they are attached, form a cyclic moiety having
from 3
to to 8 atoms in the ring, and n is an integer from 0 to 6. In certain
embodiments, Ra and
Rb are each hydrogen. In certain embodiments, a compound of the invention
comprises an a-amino acid (or a-amino acid ester), more preferably a L-a-amino
acid
or ester.
The Z, Q, Rl, R2, R3, Yl, Y2 and X groups are each independently selected such
~s that the biodistribution of the therapeutic compound for an intended target
site is not
prevented while maintaining activity of the therapeutic compound. For example,
the
number of anionic groups (and the overall charge on the therapeutic compound)
should not be so great as to inhibit traversal of an anatomical barrier, such
as a cell
membrane, or entry across a physiological barner, such as the blood-brain
barrier, in
2o situations where such properties are desired. For example, it has been
reported that
esters of phosphonoformate have biodistribution properties different from, and
in
some cases superior to, the biodistribution properties of phosphonoformate
(see, e.g.,
U.S. Patent Nos. 4,386,081 and 4,591583 to Helgstrand et al., and U.S. Patent
Nos.
5,194,654 and 5,463,092 to Hostetler et al.). Thus, in certain embodiments, at
least one
2s of Rl and R2 is an aliphatic group (more preferably an alkyl group), in
which the
aliphatic group has between 10 and 24 carbons atoms in the straight or
branched
_2,5_
CA 02338705 2001-O1-26
WO 00/06133 ,PCT/IB99/01473
chain. The number, length, and degree of branching of the aliphatic chains can
be
selected to provide a desired characteristic, e.g., lipophilicity. In other
embodiments,
at least one of R1 and R2 is an aliphatic group (more preferably an alkyl
group), in
which the aliphatic group has between 1 and 10 carbons atoms in the straight
or
branched chain. Again, the number, length, and degree of branching of the
aliphatic
chains can be selected to provide a desired characteristic, e.g.,
lipophilicity or ease of
ester cleavage by enzymes. In certain embodiments, a suitable aliphatic group
is an
ethyl group.
In another embodiment, the therapeutic compound of the invention can have
the structure:
O O
O-C-P-O-L
O-
G
NII)
in which G represents hydrogen or one or more substituents on the aryl ring
(e.g., alkyl, aryl, halogen, amino, and the like) and L is a substituted alkyl
group (in
certain embodiments, preferably a lower alkyl), more preferably a hydroxy-
~ s substituted alkyl or an alkyl substituted with a nucleoside base. In
certain
embodiments, G is hydrogen or an electron-donating group. In embodiments in
which G is an electron-withdrawing group, G is preferably an electron
withdrawing
group at the meta position. The term "electron-withdrawing group" is known in
the
art, and, as used herein, refers to a group which has a greater electron-
withdrawing
2o than hydrogen. A variety of electron-withdrawing groups are known, and
include
halogens (e.g., fluoro, chloro, bromo, and iodo groups), nitro, cyano, and the
like.
Similarly, the term "electron-donating group", as used herein, refers to a
group which
is less electron-withdrawing than hydrogen. In embodiments in which G is an
electron donating group, G can be in the ortho, meta or para position.
25 In certain embodiments, L is a moiety selected from the group consisting of
-26-
CA 02338705 2001-O1-26
WO 00/06133 ~PCT/IB99/01473
OOH
OH OH OH
IVa OC(O)C~iHz3 SC(O)C1~H~ (O)C~HIs
NHz IVb NH IVc IVd
z
N~ N N
N N I OH
N
.OH
IVe IVf IVg
Table 1 lists data pertinent to the characterization of these compounds using
art-recognized techniques.
- 27 -
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Table 1
COMPOUND 1P NMR 3C NMR FAQ
IVa -6.33(DMSO-d6) 60.97 CH20H(d, j=6Hz) 245.2
66.76 CHOH(d, J=7.8Hz)
121.65,121.78,121.99,125.71,
229.48,129.57,126.43
Aromatic CH
134.38 Aniline C-N
150.39 Phenyl C-O(d, J=7Hz)
171.57 P-C=O(d, J=234Hz)
IVb -6.41(DMSO-d6) 13.94 CH3 456
22.11, 24.40, 28.56, 28.72, 28.99,
29.00, 31.30, 33.43, -(CH~10-
65.03 CH2-OC(O)
66.60 CH2-OP(d, J=5.6Hz)
67.71 CH2-OH(d, J=6 Hz)
121.73,121.10,125.64,126.57,
20 129.40,129.95, Aromatic CH
134.04 Aniline C-N
150.31 Phenyl C-O
171.44 P-C=O(d, J=6.7 Hz)
172.83 O-C=O
2s
IVc -6.46(DMSO-d6) 13.94 CH3 471
. 22.11, 25.10, 28.68, 28.72,
28.85, 29.00, 30.76, 31.31, 32.10,
-02)10-
30 43.36 CH2-S
68.43 CH2-OH
68.43 CH-OH(d, J=6.3 Hz)
68.76 P-O-CH2-9d, J=5.8 Hz)
121.75,122.03, 225.62,126.37,
35 129.30,129.53, Aromatic CH
134.23 Aniline C-N
150.37 Phenyl C-O(d, J=6.7 Hz)
271.47 P-C=O(d, J=234.0 Hz)
198.47 S-C=O
-28-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
COMPOUND 31P NMR 1 C NMR FAB~MS(-1
IVd -6.61(DMSO-d6} 13.94 CH3 416
22.06, 25.14, 28.24, 28.35,
31.09, 32.14
-CH~6_
43.40 CH2-S
68.50 P-O-CH2-(d, J=5.8 Hz)
68.77 CH-OH(d, 6.4 Hz)
121.78,122.59,125.69,127.06,
129.43,
129.59 Aromatic CH
133.39 Aniline C-N
150.38 Phenyl C-0(d, J=6.7 Hz)
171.47 P-C=O(d, J=234.4 Hz)
198.54 S-C=O
IVe -5.76(D20) N/A N/A
20 ~ IVf -7.00(DMSO-d6) N/A N/A
IVg -6.60(DMSO-D6} 70.84 CH2-OH 321
72.17 CH-OH
121.68,121.79,121.85,125.71
127.10,
127.92,129.36,129.50,129.59
Aromatic CH
134.51 Aniline C-N
142.34 Aromatic _C-CH
30 150.37 Phenyl C-O(d, J=6.2 Hz)
171.59 P-C=O(d, J=232.6 Hz)
It will be noted that the structure of some of the therapeutic compounds of
this
invention includes asymmetric carbon atoms. It is to be understood accordingly
that
35 the isomers (e.g., enantiomers and diastereomers) arising from such
asymmetry are
included within the scope of this invention. Such isomers can be obtained in
substantially pure form by classical separation techniques and by sterically
controlled
synthesis. For the purposes of this application, unless expressly noted to the
contrary,
a therapeutic compound shall be construed to include both the R or S
stereoisomers at
4o each chiral center.
In certain embodiments, an therapeutic compound of the invention comprises a
cation (i.e., in certain embodiments, at least one of Rl, R2 or R3 is a
cation). If the
-29-
CA 02338705 2001-O1-26
WO 00/06133 .PCT/IB99/01473
cationic group is hydrogen, H+, then the therapeutic compound is considered an
acid,
e.g., phosphonoformic acid. If hydrogen is replaced by a metal ion or its
equivalent,
the therapeutic compound is a salt of the acid. Pharmaceutically acceptable
salts of
the therapeutic compound are within the scope of the invention. For example,
at least
s one of Rl, R2 or R3 can be a pharmaceutically acceptable alkali metal (e.g.,
Li, Na, or
K), ammonium canon, alkaline earth canon (e.g., Ca2+, Ba2+, Mg2+), higher
valency
canon, or polycanonic counter ion (e.g., a polyammonium canon). (See, e.g.,
Berge et
al. (197 "Pharmaceutical Salts", j. Pharm. Sci. 66:1-19). It will be
appreciated that the
stoichiometry of an anionic compound to a salt-forming counterion (if any)
will vary
to depending on the charge of the anionic portion of the compound (if any) and
the
charge of the counterion. Preferred pharmaceutically acceptable salts include
a
sodium, potassium or calcium salt, but other salts are also contemplated
within their
pharmaceutically acceptable range.
The term "pharmaceutically acceptable esters" refers to the relatively non-
toxic,
~s esterified products of the therapeutic compounds of the present invention.
These
esters can be prepared in situ during the final isolation and purification of
the
therapeutic compounds or by separately reacting the purified therapeutic
compound
in its free acid form or hydroxyl with a suitable esterifying agent; either of
which are
methods known to those skilled in the art. Carboxylic acids and phosphonic
acids can
2o be converted into esters according to methods well known to one of ordinary
skill in
the art, e.g., via treatment with an alcohol in the presence of a catalyst. A
preferred
ester group (e.g., when R3 is lower alkyl) is an ethyl ester group.
The term "alkyl" refers to the saturated aliphatic groups, including straight-
chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic)
groups, alkyl
2s substituted cycloalkyl groups, and cycioalkyl substituted alkyl groups. In
preferred
embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon
atoms in
its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), and
more
preferably 20 or fewer. Likewise, preferred cycloalkyls have from 4-10 carbon
atoms
in their ring structure, and more preferably have 4-7 carbon atoms in the ring
-30-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
structure. The term "lower alkyl" refers to alkyl groups having from 1 to 6
carbons in
the chain, and to cycloalkyls having from 3 to 6 carbons in the ring
structure.
Moreover, the term "alkyl" (including "lower alkyl") as used throughout the
specification and claims is intended to include both "unsubstituted alkyls"
and
s "substituted alkyls", the latter of which refers to alkyl moieties having
substituents
replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such
substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy,
arylcarbonyloxy, alkoxycarbonyloxy, aryioxycarbonyioxy, carboxyiate,
alkylcarbonyl,
alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate,
phosphonato,
t o phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino,
diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino,
arylcarbonyiamino, carbamoyl and ureido), amidino, imino, sulfhydryl,
alkylthio,
arylthio, thiocarboxylate, sulfate, sulfonato, sulfamoyl, sulfonamido, vitro,
trifluoromethyl, cyano, azido, heterocyclyi, aralkyl, or an aromatic or
heteroaromatic
is moiety. It will be understood by those skilled in the art that the moieties
substituted
on the hydrocarbon chain can themselves be substituted, if appropriate.
Cycloallcyls
can be further substituted, e.g., with the substituents described above. An
"araikyl"
moiety is an alkyl substituted with an aryl (e.g., phenylmethyi (benzyl)).
The term "alkoxy", as used herein, refers to a moiety having the structure -0-
2o alkyl, in which the alkyl moiety is described above.
The term "aryl" as used herein includes 5- and 6-membered single-ring aromatic
groups that may include from zero to four heteroatoms, for example,
unsubstituted or
substituted benzene, pyrroie, furan, thiophene, imidazole, oxazole, thiazole,
triazoie,
pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl
groups
2s also include polycyclic fused aromatic groups such as naphthyl, quinolyl,
indolyl, and
the like. The aromatic ring can be substituted at one or more ring positions
with such
substituents, e.g., as described above for alkyl groups. Preferred aryl groups
include
unsubstituted and substituted phenyl groups.
The term "aryloxy", as used herein, refers to a group having the structure -O-
so aryl, in which the aryl moiety is as defined above.
-31-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
The term "amino," as used herein, refers to an unsubstituted or substituted
moiety of the formula -NRaRb, in which Ra and Rb are each independently
hydrogen,
alkyl, aryl, or heteroryclyl, or Ra and Rb, taken together with the nitrogen
atom to
which they are attached, form a cyclic moiety having from 3 to 8 atoms in the
ring.
Thus, the term "amino" is intended to include cyclic amino moieties such as
piperidinyl or pyrrolidinyl groups, unless otherwise stated. An "amino-
substituted
amino group" refers to an amino group in which at least one of Ra and Rb, is
further
substituted with an amino group.
In another embodiment, R1 or R2 can be (for at least one occurrence) a long-
chain aliphatic moiety. The term "long-chain aliphatic moiety" as used herein,
refers
to a moiety having a straight or branched chain aliphatic moiety (e.g., an
alkyl or
alkenyl moiety) having from 10 to 24 carbons in the aliphatic chain, e.g., the
Long-chain
aliphatic moiety is an aliphatic chain of a fatty acid (preferably a naturally-
occurring
fatty acid). Representative long-chain aliphatic moieties include the
aliphatic chains of
~s stearic acid, oleic acid, linolenic acid, and the like.
In certain embodiments, the therapeutic compound of the invention can have
the structure:
O
I(
,P-(CY~I~)nCOOR3
RIO OI R
2
(VIII)
in which Rl and R2 are each independently hydrogen, an aliphatic group
20 (preferably a branched or straight-chain aliphatic moiety having from 1 to
24 carbon
atoms, more preferably 10-24 carbon atoms, in the chain; or an unsubstituted
or
substituted cyclic aliphatic moiety having from 4 to 7 carbon atoms in the
aliphatic
ring), an aryl group, a heterocyclic group, or a salt-forming cation; R3 is
hydrogen,
lower alkyl, aryl, or a salt-forming cadon; Yl and Y2 are each independently
2s hydrogen, halogen (e.g., F, Cl, Br, or I), lower alkyl, hydroxy, alkoxy, or
aryloxy; and n
is an integer from 0 to 12. Suitable therapeutic compounds for use in the
invention
include compounds in which both Rl and Rz are pharmaceutically acceptable salt-
forming cations. In a particularly suitable embodiment, Rl, R2 and R3 are each
-32-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
independently a sodium, potassium or calcium cation, and n is 0. In certain
embodiments of the therapeutic compounds, Yl and Y2 are each hydrogen.
Suitable
therapeutic compounds include salts of phosphonoformate. Trisodium
phosphonoformate (foscarnet sodium or Foscavir~) is commercially available
(e.g.,
from Astray, and its clinical pharmacology has been investigated (see, e.g.,
"Physician's
Desk Reference", 51st Ed., pp. 541-545 (1990.
In another embodiment, the therapeutic compound used in the invention can
be an aminophosphonate, a biphosphonate, a phosphonocarboxylate derivative, a
phosphonate derivative, or a phosphono carbohydrate. For example, the
therapeutic
to compound can be one of the compounds described in Appendix A submitted
herewith.
Suitable therapeutic compounds for inclusion in a pharmaceutical composition
for treating glycosaminoglycan-associated molecular interactions include 1,3-
propanedisulfonic acid, 3-amino-1-propanesulfonic acid, 3-dimethylamino-1-
~s propanesulfonic acid sodium salt, 2-(3-sulfopropyl)-1,2,3,4-tetrahydro-9H-
pyrido[3,4-
b]indole, sodium salt, 3-[2-(6-methoxy-1,2,3,4-tetrahydroisoquinolinyl)]-1-
propanesulfonic acid, 3-(2-hydroxyethyl)amino-1-propanesulfonic acid, 3-(3-
hydroxy-
1-propyl)amino-1-propanesulfonic acid, (-)3-[(R)-2-hydroxy-1-propyl]amino-1-
propanesulfonic acid, 3-(4-hydroxy-1-butyl)amino-1-propanesulfonic acid, 3-(5-
2o hydroxy-1-pentyl)amino-1-propanesulfonic acid, 3-(6-hydroxy-1-hexyl)amino-1-
propanesulfonic acid, 3-(2-hydroxyethyl)amino-1-propanesulfonic acid, 3-(2-
hydroxyethyl)amino-1-propanesulfonic acid, 3-(2-hydroxyethyl)amino-1-
propanesulfonic acid, 3-(2-hydroxyethyl)amino-1-propanesulfonic acid, 3-
hexylamino-
1-propanesulfonic acid, 3-undecylamino-1-propanesulfonic acid, and 3-
2s octadecylamino-1-propanesulfonic acid, and pharmaceutically acceptable
salts or
esters thereof.
In the methods of the invention, a condition related to a glycosaminoglycan-
associated molecular interaction in a subject is treated by administering a
therapeutic
compound of the invention to the subject. The term "subject" is intended to
include
30 living organisms in which conditions related to glycosaminoglycan-
associated
-33-
CA 02338705 2001-O1-26
WO 00/06133 ~PCT/IB99/01473
molecular interactions can occur. The term subject is also intended to include
those
living organisms which are afflicted by infectious agents which secrete
components
which interfere with a host cells via glycosaminoglycans. Examples of subjects
include
humans, monkeys, cows, sheep, goats, dogs, cats, mice, rats, and transgenic
species
s thereof. Administration of the compositions of the present invention to a
subject to be
treated can be carried out using known procedures, at dosages and for periods
of time
effective to treat a condition related to a glycosaminoglycan-associated
molecular
interaction in the subject. An effective amount of the therapeutic compound
necessary
to achieve a therapeutic effect may vary according to factors such as the age,
sex, and
t o weight of the subject, and the ability of the therapeutic compound to
treat the foreign
agents in the subject. Dosage regimens can be adjusted to provide the optimum
therapeutic response. For example, several divided doses may be administered
daily
or the dose may be proportionally reduced as indicated by the exigencies of
the
therapeutic situation. A non-limiting example of an effective dose range for a
~s therapeutic compound of the invention (e.g., poly(vinylsulfonate sodium
salt)) is
between 5 and 500 mg/kg of body weight/per day. In an aqueous composition,
suitable concentrations for the active compound (i.e., the therapeutic
compound that
can treat the disease) are between 5 and 500 mM, between 10 and 100 mM, and
between 20 and 50 mM.
2o The therapeutic compounds of the invention may be administered orally.
Alternatively, the active compound may be administered by other suitable
routes such
subcutaneous, intravenous, intraperitoneal, etc. administration (e.g. by
injection).
Depending on the route of administration, the active compound may be coated in
a
material to protect the compound from the action of acids and other natural
2s conditions which may inactivate the compound.
The compounds of the invention can be formulated to ensure proper
distribution in vivo. For example, the blood-brain barrier (BBB) excludes many
highly
hydrophilic compounds. To ensure that the therapeutic compounds of the
invention
cross the BBB, they can be formulated, for example, in liposomes. For methods
of
3o manufacturing liposomes, see, e.g., U.S. Patents 4,522,811; 5,374,548; and
5,399,331.
_3r~_
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
The liposomes may comprise one or more moieties which are selectively
transported
into specific cells or organs ("targeting moieties"), thus providing targeted
drug
delivery (see, e.g., V.V. Ranade (1989) J. Clin. Pharmacol. 29:685). Exemplary
targeting
moieties include folate or biotin (see, e.g., U.S. Patent 5,416,016 to Low et
al.);
s mannosides (Umezawa et al., (1988) Biochem. Biophys. Res. Commun.153:1038);
antibodies (P.G. Bloeman et al. (1995) FEBS Lett. 357:140; M. Owais et al.
(1995)
Antimicrob. Agents Chemother. 39:180); surfactant protein A receptor (Briscoe
et al.
(1995) Am. j. Physiol.1233:I34); gp120 (Schreier et al. (1994) j. Biol. Chem.
269:9090); see
also K. Keinanen; M.L. Laukkanen (1994) FEBS Lett. 346:123; J.J. Killion; LJ.
Fidler
to (1994) Immunomethods 4:273. In an embodiment, the therapeutic compounds of
the
invention are formulated in liposomes; in a more preferred embodiment, the
Iiposomes include a targeting moiety.
Delivery and in vivo distribution can also be affected by alteration of an
anionic
group of compounds of the invention. For example, anionic groups such as
~s carboxylate or tetrazole can be employed instead of, or in addition to,
sulfate or
sulfonate moieties, to provide compounds with desirable pharmocokinetic,
pharmacodynamic, biodistributive, or other properties: Exemplary tetrazole-
substituted compounds include 3-(1H tetrazol-5-yl)-9H-thioxanthen-9-one 20,10-
dioxide (LXIV), 5,5-dithiobis(1-phenyltetrazole) (LXV),1H tetrazole (LXVI), 5-
phenyl-
20 1H-tetrazole (LXVII), and 5-(2-aminoethanoic acid)-1H-tetrazole (LXVIII),
and the like;
and their pharmaceutically acceptable salts. Exemplary carboxylate-substituted
compounds include dicarboxylic acids such as adipic acid, azelaic acid, 3,3-
dimethylglutaric acid, suberic acid, succinic acid, and the like, and their
pharmaceutically acceptable salts.
25 To administer the therapeutic compound by other than parenteral
administration, it may be necessary to coat the compound with, or co-
administer the
compound with, a material to prevent its inactivation. For example, the
therapeutic
compound may be administered to a subject in an appropriate carrier, for
example,
liposomes, or a diluent. Pharmaceutically acceptable diluents include saline
and
-35-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
aqueous buffer solutions. Liposomes include water-in-oil-in-water CGF
emulsions as
well as conventional liposvmes (Strejan et al., (1984) J. Neuroimmunol. 7:2~.
The therapeutic compound may also be administered parenterally,
intraperitoneally, intraspinally, or intracerebrally. Dispersions can be
prepared in
glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under
ordinary conditions of storage and use, these preparations may contain a
preservative
to prevent the growth of microorganisms.
Pharmaceutical compositions suitable for injectable use include sterile
aqueous
solutions (where water soluble) or dispersions and sterile powders for the
extemporaneous preparation of sterile injectable solutions or dispersion. In
all cases,
the composition must be sterile and must be fluid to the extent that easy
syringability
exists. It must be stable under the conditions of manufacture and storage and
must be
preserved against the contaminating action of microorganisms such as bacteria
and
fungi. The Garner can be a solvent or dispersion medium containing, for
example,
15 water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid
polyethylene glycol, and the like), suitable mixtures thereof, and vegetable
oils. The
proper fluidity can be maintained, for example, by the use of a coating such
as lecithin,
by the maintenance of the required particle size in the case of dispersion and
by the
use of surfactants. Prevention of the action of microorganisms can be achieved
by
2o various antibacterial and antifungal agents, for example, parabens,
chlorobutanol,
phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be
preferable to
include isotonic agents, for example, sugars, sodium chloride, or polyalcohols
such as
mannitol and sorbitol, in the composition. Prolonged absorption of the
injectable
compositions can be brought about by including in the composition an agent
which
25 delays absorption, for example, aluminum monostearate or gelatin.
Sterile injectable solutions can be prepared by incorporating the therapeutic
compound in the required amount in an appropriate solvent with one or a
combination of ingredients enumerated above, as required, followed by filtered
sterilization. Generally, dispersions are prepared by incorporating the
therapeutic
3o compound into a sterile carrier which contains a basic dispersion medium
and the
-36-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
required other ingredients from those enumerated above. In the case of sterile
powders for the preparation of sterile injectable solutions, the preferred
methods of
preparation are vacuum drying and freeze-drying which yields a powder of the
active
ingredient (i.e., the therapeutic compound) plus any additional desired
ingredient
from a previously sterile-filtered solution thereof.
The therapeutic compound can be orally administered, for example, with an
inert diluent or an assimilable edible carrier. The therapeutic compound and
other
ingredients may also be enclosed in a hard or soft shell gelatin capsule,
compressed
into tablets, or incorporated directly into the subject's diet. For oral
therapeutic
to administration, the therapeutic compound may be incorporated with
excipients and
used in the form of ingestible tablets, buccal tablets, troches, capsules,
elixirs,
suspensions, syrups, wafers, and the like. The percentage of the therapeutic
compound in the compositions and preparations may, of course, be varied. The
amount of the therapeutic compound in such therapeutically useful compositions
is
~ s such that a suitable dosage will be obtained.
It is especially advantageous to formulate parenteral compositions in dosage
unit form for ease of administration and uniformity of dosage. Dosage unit
form as
used herein refers to physically discrete units suited as unitary dosages for
the
subjects to be treated; each unit containing a predetermined quantity of
therapeutic
2o compound calculated to produce the desired therapeutic effect in
association with the
required pharmaceutical carrier. The specification for the dosage unit forms
of the
invention are dictated by and directly dependent on (a) the unique
characteristics of
the therapeutic compound and the particular therapeutic effect to be achieved,
and (b)
the limitations inherent in the art of compounding such a therapeutic compound
for
2s the treatment of a condition related to a glycosaminoglycan-associated
molecular
interaction in a subject.
Active compounds are administered at a therapeutically effective dosage
sufficient to treat a condition related to a glycosaminoglycan-associated
molecular
interaction in a subject. A "therapeutically effective dosage" preferably
reduces the
3o amount of symptoms of the condition in the infected subject by at least
about 200,
- 37 -
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
more preferably by at least about 40°~, even more preferably by at
least about 60~°,
and still more preferably by at least about 80% relative to untreated
subjects. For
example, the ability of a compound to reduce an infectious agent can be
evaluated in
an animal model system that may be predictive of efficacy in treating diseases
s associated with the infectious agent in humans.
Referring now to the drawings, Figures 15-28 illustrate the efficacy of
compounds of the invention in inhibiting binding of certain chemolcines to
heparin-
coated wells in an ELISA assay. The compounds referenced in the drawings
are:1) 3-
amino-1-propanesulfonic acid, sodium salt; 2) trisodium phosphonoformate; 3)
methylene diphosphonic acid; 4) trehalose octasulfate, octasodium salt; 5)
traps-4-
hydroxy-L-proline-4-sulfate, disodium salt; 6) nitrilo(methylene)
triphosphonic acid;
7) poly(vinylsulfonate}, sodium salt (PVS501, Aldrich); 8) 3-[-2-6-methoxy-
1,2,3,4-
tetrahydroisoquinolinyl)]-1-propanesulfonic acid; 9) 3-
phosphonopropanesulfonic
acid, trisodium salt;10); 4,5-dihydroxy-1,3,benzenedisulfonic acid, sodium
salt;11) 3-
~s cyclohexylamino-1-propanesulfonic acid;12) O-phospho-L-serine; and 13) 2-
thiopheneboronic acid.
Figures 15 and 16 are included to illustrate the specificity of the ELISA for
RAN I'ES binding to heparin coated wells. Figure 15 shows heparin inhibiting
RANTES binding in a dose-dependent manner. Figure 16 shows heparin inhibiting
2o RANTES binding in a dose-dependent manner using a fixed concentration of
RANTES. Figure 17 shows the inhibition of RANTES binding by compounds 7, 8, 9
and 10. Figure 18 shows the inhibition of RANTES binding by compounds 11,12
and
13. Figure 21 depicts the concentration-dependent inhibition of RANTES binding
by
compound 4. Figure 27 compares the concentration-dependent inhibition of
RANTES
2s binding by compounds 4 and 5.
Figure 28 illustrates the inhibition of IL-8 binding by compounds 1, 2 and 3.
It
can be seen that compound 1 shows concentration-dependent inhibition of IL-8
binding. Figure 20 illustrates the inhibition of IL-8 binding by compounds 7-
13. It can
be seen that compound 7 shows dose-dependent inhibition of IL-8 binding.
Figure 22
so illustrates the inhibition of IL-8 binding by compound 3.
_3g_
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Figure 19 illustrates the inhibition of EOTAXIN binding by compounds 7-10. It
can be seen that compound 7 shows dose-dependent inhibition of EOTAXIN
binding.
Figure 24 illustrates the concentration-dependent inhibition of EOTAXIN
binding by
compound 4. Figure 25 illustrates the inhibition of EOTAXIN binding by
compound
6. Figure 26 illustrates the inhibition of EOTAXIN binding by compound 3.
Figure 23 is a comparison of the binding inhibition of RANTES, EOTAXIN and
IL-8 by compound 7. It can be seen that compound 7 shows concentration-
dependent
inhibition of EOTAXIN and IL-8 binding.
The invention is further illustrated by the following Exemplification, which
~o should not be construed as further limiting the subject invention. The
contents of all
references, issued patents, and published patent applications cited throughout
this
application including the background are hereby incorporated by reference.
EXEMPLIFICATION
Bacteria:
~ s Streptococcus pyogens:
' S. pyogenes can cause acute rheumatic fever streptococcus and acute post-
streptococcal glomerulonephritis. Studies have identified the protein
responsible for
stabilizing the bacteria on the basal laminae of cardiac muscle as well as on
kidney
tissues.
2o The mechanism for such a bacterial virulence is unknown. One hypothesis is
the direct binding of bacterial adhesions and exotoxins to the cardiac muscle
and
kidney _ Bergey & Stenson identified two streptococcal proteins (9,15 Kda)
that are
capable of binding to basement membranes of cardiac muscle and renal tissues;
the
binding was completely inhibited by heparin and other GAGS. Binding of
specific S.
2s pyogenes protein can be measured on cardiac muscle section and kidney
section.
Briefly, S. pyogenes protein preparation are incubated on cardiac muscle and
kidney
preparation. Binding of protein is visualized by indirect immunofluorescence
using
an antibody against the bacteria protein. Ability of a compound to interfere
in such a
binding can be determined in ligand inhibition studies. Binding is measured by
so comparing the amount of protein binding (as determined by Image Analysis)
in
presence or absence of the compound. Measurement can also be determined using
3H-labeled streptococcal protein.
-39-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Fluorescence: Cryostat-cut section of heart tissue are pre-incubated with
bacterial antigen preparation. Amount of peptide binding to tissue is
determined by
indirect immunofluorescence using a Rabbit anti-S. pyogenes serum. Ability of
a
compound to inhibit the binding of the streptococcal protein to the tissue is
evaluated
by comparing the amount of bacterial antigen present of tissue section in
presence or
absence of the inhibitor.
Direct Binding Assay: Radiolabelled streptococcal components are tested for
direct binding activity to mammalian tissue component as previously described
(MW
Stinson & EJ Bergey,1982). Dried cardiac muscle fragments are rehydrated with
PBS
to and 1% bovine serum albumin. Moist heart material is incubated with
radiolabelled
bacterial components. Bound radioactivity is determined by liquid
scintillation
spectrometry.
Determination of a compound's ability to inhibit this binding is done with
various concentrations of the compound added to the streptococcal preparation
prior
t5 its incubation with the cardiac muscle preparation.
S, aureus, Pseudomonas aeruglnosa, Legionella pneumophila
S. aureus and P. aeruginosa are well-known to cause major pulmonary infection
in patients with cystic fibrosis. Legionella pneumophila is known to cause
Legionnaire's
disease in susceptible individuals. These bacteria need to adhere to mucus
membrane
2o to in order to multiply and cause infection.
The ability of specific compounds to inhibit S. Aureus, P. Aeruginosa and L.
pneumophila adherence to mucosal membrane can be determined in vitro using
marine
trachea culture. The number of bacteria adhering to the preparation can be
determined by comparing the number of bacteria remaining in supernatant after
2s incubation with trachea preparation. Briefly, trachea preparation are
incubated with a
bacterial suspension in presence or absence of a compound. 30 minutes later
the
amount of bacteria remaining the supernatant (i.e., non-adhering) determined
by
serial dilution.
The ability of bacteria to infect cells an also be determined in vitro.
so Macrophages are incubated with bacteria and the phagocytic rate is
determined 30
minutes Later.
-40-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
In vivo: Intratracheal infection with P. aeruginosa or S. aureus with or
without
treatment with compound. Intratracheal infection with P. aeruginosa, S. aureus
and
Legionella have been shown to cause acute pulmonary infection in mice. The
ability of
a compound to inhibit such an infection can be determined by evaluating the
bacterial
s load present in the lung of infected mice undergoing a treatment with
specific
compounds. These compounds can be administered IV, PO, or under aerosol.
Viral infections:
The infectious process of viruses of the herpesviridae family have been
extensively studied. It has been established that the initial interaction of
several
~o herpes viruses with the cell surface is mediated by glycosaminoglycans
found on the
proteoglycans in the cell plasma membrane. These GAGs are similar to heparin.
Amongst the different herpes viruses found to interact with cell surface GAGs,
interesting ones are Cytomegalovirus (CMV) and Herpes simplex (HSV-1 and HSV-
2).
The ability of compounds to interfere in the infectious process of these
viruses is
t s determined as follows:
In vitro: Hela cells are infected with CMV or HSV-1 in presence or absence of
compounds. Ability of CMV to infect cells is determined by evaluating virus
load 24-
72 hours later by:
~ ~ viral antigen expression (IF)
20 ~ specific viral antigen (mRNA level)
~ Virus particle titration
~ cytopathic effect
The ability of a compound to interfere in the infectious process can be
determined by evaluating (by the different techniques mentioned above) the
amount
2s of virus found in the culture in presence or absence of an inhibitor.
EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more
than routine experimentation, numerous equivalents to the specific procedures
described herein. Such equivalents are considered to be within the scope of
this
3o invention and are covered by the following claims.
-41-
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Appendix A
AMINOn~3osr~orr.~.T~cs
Name Structure
3-[2-( 1,2,3 ,4-Tetrahydroisoquino linyl)]-1-
propanephosphonic acid, disodium salt I ~ N p oNa
~'i~ ~ h
3-Aminopropylphosphonic acid NH2~-I2~2~ipp3Hl
(S~-2-Amino-2-methyl-4- H Pa(p
phosphonobutanoic acid H ~~ Hh
2 3
o-(-)-2-Amino-4-phosphonobutanoic acid ~H
H~
HZN PO(OH}~
~-(+)-2-Amino-4-phosphonobutanoic acid H
H I~L.
H~ PO(OHh
3-Aminopropyl(methyl)phosphinic acid,
hydrochloride HiN~p-OH HCl
Me
(R)-(-)-3-(2-Carboxypiperazin-4 yl)- ~~HzCHipp~HZ
propyl-1-phosphonic acid (D-CPP) N
C 1-H
,~'~~H
H
(R,~-4-(3-Phosphonoprop-2-
enyl)piperazine-2-carboxylic acid . H
CNl 'H
~ ~:,~H
H
42
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
~rans-L-4-Phosphonomethylproline, Na02c H
trisodium satlt
CH=P(OxONa}i.
cis-t,-4-Phosphonomethylproline, NaOic H
trisodium salt
CHZP(OXONa}i
4-Amino-I-butylphosphonic acid, O
disodium salt ~P(~Nah
HiN
1-(3-Phosphonopropyl)-benzimidazole, O
disodium salt ;~i~z~iP(~~h
I N
3 Dimethylamirio-1-propytphosphonic O
acid, disodium~salt Me2NCH2CH2CHiP(ONah
3-Amino-butylphosphonic acid, ~PO~Naz
disodium salt
MiI
3 Amino-pentylphosphonic acid, Po3Nai
disodium salt
- NHZ
3-Amino-hexylphosphonic acid, PO~Na~
disodium salt
NHZ
43
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/014'13
3-Amino-hepiylphosphonic acid, PoiNai
disodium salt
NH2
3-Amino-octylphophonic acid, ~PO3Na=
disodium salt
NH=
3-Amino-4-methyl-pentylphosphonic acid,
disodium salt ~~~Na=
' NH~=
3-Amino-3-methyl-butylphosphonic acid, P03Nas
disodium salt
NN=
3-Amino-3-phenyl-propylphosphonic _
acid, ~ ~ PO~Nai
disodium salt
~z
3-Amino-4-phenyl-butylphosphonic acid,
disodium salt ' ~ ~Na=
NHz
3-Amino-4-phenyl-pentylphosphonic acid,
disodium salt ~ ~ P03Na2
~i
3-Amino-3-phenyl-butylphosphonic acid
disodium salt ' /
P4~Na2
NH:
44
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99101473
2-Amino-2-(2-phosphonoethyl)-I,3,4- NHi
trihydronaphthalene, disodium salt ~ ~ pp3Na2
1-Amino-1-(2-phosphonoethyl)- NHi
cyclohexane, disodium salt
PO3Na=
2-(2-Amino-4-
phosphonobutoxy)tetrahydropyran PO~Nai
O O
NH=
3-Amino-4-hydroxy-butylphosphonic HO~WNaz
acid, NHi
disodium salt
Diethyl 2-pyrrolidinylphosphonate
P(~Hsh
O
H
2-pyrrolidinylphosphonic acid, disodium
~t ~ P(ONa}~
H O
1,1-Dioxo-2-(3-phosphonopropyl)- ~~p~O~h
isothiazoline, disodium salt
O
O
2-Dcoxy-2-phosphonoacetylamino-D- H
glucose O
OH OH
O
HO ~~2P~ONay~
45
SUBSTITUTE SHEET (RULE 2B)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
3-Hydroxy-3-(2-pyridyl)propenyl-2-
phosphonic acid, disodium salt
~N
P(ONah
O
3-Hydroxy-3-(3-pyridyl)propenyl-2- ~ ~ off
phosphoric acid, disodium salt
N.
/~ ~P(ONah
O
3-Hydroxy-3-(4-PYi'idyl)propenyl-2-
phosphoric acid, disodium salt
~P(oNa}I
O
3-Amino-3-(2-pyridyl)propcnyl-2-
phosphoric acid, disodium salt
/~P(oNah
0
3-Amino-3-(3-pyridyl)propenyl 2-
phosphoric acid, disodium salt i
P(ONah
a
O
46
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
3-Amino-3-(4-pyrzdyl)propenyl-2-
phosphonic acid, disodium salt N~ ~ NHi
P(ONah
O
1,4-Diamino-I-(3-pyridyl)butyl-2- ~ ~ Nf.t=
phosphoric acid, disodium salt N
PO~Na=
NHi
1,4-Diamino-4-methyl-I-{3-
pyridyl)pentyl-2-phosphoric acid, ~ ~
disodium salt N
POyNaZ
NH:
1,4-Diamino-4-methyl-1-(2-
pyridyl)pentyl-2-phosphoric acid, ' w 'N~h
disodium salt '
~PO~Na=
NH:
I,4-Diamino-4-methyl-1-(4-
pyridyl)pentyl-2-phasphonic acid, ~ NHi
disodium salt
PO~Na= .
NH=
3-(Z-Amino-4,5,7,8-tetrahydro-6H -
thiazolo[4,5-djaupin-6-yl)propyl- Hir(-.-(.N ~ N~1'(ONah
phosphoric acid, disodium salt
47
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 ~ PCT/IB99/01473
N Phosphonomethylglycine O
~ phPQ-~ZNHCH2000H
N Phosphonomcthylglycine, trisodium salt p
(Na0}ZPCHxNHCHxO00Na
(2R,4,S~-4-Phosphonomethylpipecolinic O
acid, trisodium salt ~.P(ONah
N~'''GdZNa
H
(2R, 4S~-4-P hospho no methyl- O
pipecolinamide, disodium salt ..-P(ONa)i
N~''' ~C~Hx
H O
N Phosphonomethylglycine O
(Aldrich, see NC-1769) ~ 0h~'~x~~x~H
N Phosphonomethylglycinc, trisodium salt p
(see NC1770, prcparcd from NC178I) (NaohPCH2NHCfi2OOOl~
3-[6-Methoxy-2-(1,2,3,4-tetrahydro- Me0
isoquinolinyl)]propylphosphonic acid, ~ 1 N~pplNa2
disodium salt
48
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PC'T/IB99/01473
3-[8-Methoxy-2-{ 1,2,3,4-tetrahydro
isoquinolinyl)]propylphosphonic acid,
disodium salt ~ N~PgNa=
OMe
3-[2-(3-Methoxycarbonyl-1,2,3,4- Op=Me
tetrahydroisoquinolinyl)]-
propylphosphonic acid disodium salt ~ ~ N~~~Na=
2-(3-Phosphonopropyl)-1,2,3,4- ~
tetrahydro-9H pyrido[3,4-b]indole, ~
disodium salt ~ N N~ ~Nai
H
49
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PC'T/IB99/01473
Bisphosplionates
I~Iame Structure
Pamidronic acid (3-Aminopropyl-1- PO~Hz
hydroxypropane-1,1-bisphosphonic acid) HzN~POzHZ
OOH
3-Amino-1-hydmxygropane-1,1- PosNa2
bisphosphonic acid, tetrasodium salt HiNw/~-~~z
OH
I-Amino-3-sulfopropane-1,I- PgHz
bisghosphonic acid HOsS~POzHz
~z
I-Amino-3-sulfopropane-I,1- ~~z
tiisphosghonic.acid, pentasodium salt NaO3S~POzNaz
'~z
1,3-Diaminopropane-I,1-bisphosphonic Po3Na=
acid, tetrasodium salt H=N~PO3t~ta=
~z
1-Amino-3-dimethylaminopropane-1,I- ~ POlNaz
bisphosphonic acid, tctrasodium salt ~N~~Naz
~z
3-Dimethylamino-I-hydroxypropane-1,1- ~ Po~ldaz
bisphosphonic acid, tetrasodium salt ~N~~~z
OH
50
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
1-Hydroxy-3-(methylphenylamino)- N~ ~pNp~Na
propano-l,l-bisphosphonic acid, i I i
tetrasodium salt OH
1-ono-3-(methylphenylamino)propane- ~ P03NaZ
1,1-bisphosphonic acid, tetrasodium salt ~ N~~3Nai
w I ~i
Ibandronic acid, tetrasodium salt I ~Na2
( 1-Hydroxy-3-(methylpentylamino)- ~N~'~~Nai
propane-I,I-bisphosphonic acid, OH
tctrasodium salt)
1-Amino-3-(methylpentylamino)propane- I POsNaZ
1,1-bisphosphonic acid, tetrasodium salt ~N~'~~Nai
NHi
1-Amino-3-(1 benzimidazolyl)propane- Nf'Iz
I:~'~aHi
1,1-bisphosphonic acid
~Hi
1-Amino-3-(1-benzimidaz~olyl)propane- Nt'~
~/~' P03Nai
1,1-bisphosphbnic acid, tetrasodium salt
r~PO~Nai
N
a ->
3-Aminopropane-1,1-bisphosphonic acid, HzN~PO~Na~
tetrasodium salt
POsNa=
51
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
(d~-3-Aminobutane-1,1-bisphosphonic ~pO~Nai
acid, tetrasodium salt
NHZ P03NaZ
(d~-3-Aminopentane-1,1-bisphosphonic ~~p03Nai
acid, tetrasodium sal ' 't
NH= POsNa1
(d~-3-Aminohexane-1,1-bisphosphonic PO3Na=
acid, tetr~asodium salt
NHZ P03Na2
(d~-3-Aminoheptane-1,1-bisphosphonic pO~Nai
acid, tetrasodium salt
NH2 P03Nai
(d~-3-Aminooctane- I,1-bisphosphonic P03Nai
acid, tetrasodium salt
NH2 P03Na=
(dn-3-Amino-4-methylpcntane-I,1-
bisphosphonic~acid, tetrasodium salt i~PO3Nai
1NHZ 'P03NaZ
(d~-3-Amino-3-mcthylbutanc-I,1- '~ /P03Nai
bisphosphonic acid, tetrasodium sal ~ Tt
NHz ~W
(d~-3-Amino-3-phenylpropane-I, I-
bisphosphonic acid, tctrasodium salt ~ ~ p~~Nai
~2 ~1~2
(d~-3-Amino-4-phenylbutane-1, I- ~ POsNai
bisphosphonic acid, tetrasodium salt
ttH: PO~Na=
52
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
(d~-3-Amino-4-phenylpentane-1,1-
bisphosphonic acid, tetrasodium salt ~ ' PO~Nai
NH= PO~Nai
(dn-3-Amino-3-phenylbutane-1,1-
bisphosphonic acid, tetrasodium salt
PO~Na2
Nfi2 P03Na=
(d~-2-(2-Amino-1,2,3,4- NH2 Po3Nai
tetrahydronaphthalenyl)ethane-1,1- ~ ~ pO~L~a2
bisphosphonic acid, tetrasodium salt
2-(1-Aminocyclohexyl)ethane-1,1- ~2POsNa2
bisphosphonic acid, tetrasodium salt
POsNa2
2-(2-Acnino-4,4-bisphosphonobutoxy)-
tetrahydropyran, tetrasodium salt ~PO~Nas
OO1
NHx POsNa2
(d~-3-Amino-'1-hydroxybutane-1,1- PO3Na~,
bisphosphonic acid, tetrasodium salt HO'~
pO3NaZ
(S~-Hydroxy(2-pyrrolidinyl)methane- HO. H
bisphosphonic acid tetrasodium salt ~2osp
NaZO~P
Hydroxy[(~~ 4R)-4-hydroxy-2-
pyrrolidinyl]methanebisphosphonic acid
tctrasodium salt Na2OsP
OH
53
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
2-Amino- I -hydroxyethane- l, I - OH
bisphosphonic acid, tetrasodium salt NHiCHio(PO~Na~
1,2-Diaminoethane-1,I-bisphonponic acid, NH2
tctrasodium salt NHsCH~O(P03Na~
4-Amino-1-hydroxybutane- I, I - OH
bisphosphonic acid, tetrasodium salt NHxCH=CH2CH2U(P03Na~
1,4 Diaminobutanc-1,I-bisphosphonic NHz
acid, NH~CHxCH2CHzC(F'OsNa?h
tetrasodium salt
S-Amino-1-hydroxypentane-1, I - off
bisphosphonic acid, tetrasodium salt NHiCHiCHICHzCHIC(PO~Na~
1,5-Diaminopentane-1,1-bisphosphonic NHZ
acid, NH2CH=CHiCHZCHiO(1'07N8~)2
tCttaSOdIUm SAIL
(S~ 2-Amino-1-hydroxypropane-1,I- NH=
bisphosphonic acid, tetrasodium salt
~~s~x
OH
(S~-2-Amino-1-hydroxybutane-I,1- ~tZ
bisphosphonic acid, tetrasodium salt
POsNa1
OH
(,S'-2-Amino-I-hydroxy-3-methylbutane- NH=
1,1-bisphosphonic acid, tetrasodium salt = ~~~:
~a~:
off
54
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
(S)-2-Amino-1-hydroxy-3-phenylpropane-
1,I-bisphosphonic acid, tetrasodium salt I ~ = pO~NaZ
PO~Naz
OH
(S~-2-Amino-1,3-d ihydroxypropane-1,1- NHi
bisghosphonic acid, tetrasodium salt HO~
~~Wi
OH
(S~ 2,3-Diamino-1-hydroxypropane-l,l- NHi
bisphosphonic acid, tetrasodiurn salt HiN
PO~Nai
OH
(dn-3-Amino-1-hydroxy-3- H N
phenylpropane-1,1-bisphosphonic acid, ~ ~P03Na=
tetrasodium salt ~ off
l i
(S')-3-Amino ~-(4-chlorophenyl)-1-
hydroxypropane-1,1-bisphosphonic acid,
tctrasodium salt
~~i
(S~ 2-Amino-3-(4-aminophenyl)-1- HiN
hydroxypropane-1,1-bisphosphonic acid, I ~ ~~ pO;~i
~'-PO~Na=
tctrasodium salt
OH
55
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Phosphonocarbo~:ylate Derivatives
hIamc Structure
Phosphonoacetic acid (fosfonet) O
~P\ OH
HO OH
Phosphonoformic acid, trisodium salt
Na0' / P~ ONa
ONa
O
Diethylphosphonoacetic acid i~ O
'OH
C;H3CHx0
x~l
2-Carboxyethylphosphonic acid HploCH=CHZPO3Hz
(d~-2-Amino-3-phosphonopropanoic NHx
acid H~.~~i~HZ
(d~-2-Amino-5-phosphonopentanoic acid NHx
HOiOCfiCHxCHxCHxPC~Ix
Phosphonoacetic acid (Sec NC-769) HoioCHxPO~Hx
(S~-2-Amino-2-methyl-4- Ho=C~t'aCOt~x
phosphonobutanoic acid
56
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99I01473
p-(-)-2-Amino-4-phosphonobutanoic acid po?H
H,..1. ~
H2N~ p~COH}~
L-(+)-2-Amino-~-phosphonobutanoic H ~, ~H
2 1 _
acid H~ pO(OHh
p~-)-2-plnino-7-phosphonohcptanoic COIH
YO(OH}i
acid H""
HZN
L.~+)_2_~ino-7-phosphonohcptanoic ~H
acid H=N.... pp~pHy~
p-(-)-2-Amino-6-phosphonohcxanoic Co~H
acid H"' 0
HiN
L-(+)-2-Amino-6-phosphonohexanoic ooiH
acid H=N,...
H PO(CHh
p-( )-2-Amino-4-phosphonopentanoic C~H
acid H ~~~o~
L~+)_2-Amino..4.:phosphonopentanoic - ~H
~POcoHh
acid HiN,..
H
p-( ) 2-Amino-3-phosphonopropanoic
acid H ~~1'o(oHh
~-(+)-2-Amino-3-phosphonopropanoic ~H
acid H: H~PO(OHh
57
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
(R)-(-)-3-(2-Carboxypiperazin-4-yl)- CHiCHzCHiPOsHi
propyl-1-phosphoric acid (D-CPP) N
CN- 'H H
H
~-4-[Difluoro(phosphono)methyl}J- O _
phcnylalaninc CF PO(OHh
HO
T!H=
(R,~-4-(3-Phosphonoprop-2- CHiCH~HPOjHi
enyl)piperazine-2-carboxylic acid N
C 1-H
~~''O~H
H
traps-~-4-Phosphonomethylproline, NaOi H
trisodium salt N
CHiP(OXONa}i
cis-t.-4-Phosphonomethylproline, Nao2C H
trisodium salt N
CHip(OXONa}~
N.N Diethylphosphonoacetamide,
disodium salt
~O 'iP-ONa
g2N~ ~
ONa
N Cyclohexylphosphonoacetamide,
~O ~(p-ONa
disodium salt
N'
o- H ONa
58
SU9STITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Phosphonoacetic hydrazide, disodium O
salt
P-ONa
NH~NH pNa
N Hydroxyphosphonoacetamide,
disodium salt
~O /(P-ONa
HONH'
ONa
N Phosphonoacetyl-L-atanine, trisodium O O OoONa
~t Na0-~P~W
Na0 H
N Phosphonoacetyl-~-glycine, trisodium il O
salt ~ Na0- P
Na0 NHCHZCOONa
N-(Phosphonoactyl)-L-asparagine-c.- o 0
glycine, tetrasodiucn salt '°
Na0-~P~ NHQi:00tNa
Na0
O
N Phosphonomethylglyeine O
HOhPCH2NHCH2000H
N Phosphonomethylglycine, trisodium O
Salt (Na0)=PCHZNHCH=OC3bNa
2-Phosphonomethylglutaric acid, O GOZNa
Na0-P~~ ~
tetrasodium salt
ONa i
59
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 ~PCT/IB99/01473
2-Phosphonomcthylsuccinic acid, O CoZNa
tetrasodium salt Na0-P~~zNa
ONa
(2R,4S~-4-Phosphonomethylpipecolinic
O
acid, trisodium salt ,..~p(oNah
hI~~'''OOiNa
H
(2R,4S~-4-Phosphonomethyl- O
pipecolinamide, disodium salt r,.~p(ONa~
~...
N ~CNIi.
H O
N Phosphonomethylglycine O
(Aldrich, see NC-1769) (HO}~PCH~NHCH~COOH
N Phosphonomethylglycine, trisodium O
salt (Naoy~PCHZNHCHZO00Na
(seeNC1770, prepared fromNC1781)
3-[2-(3-Methoxycarbonyl-1,2, ~,4- ~Me
tctrahydroisoquinolinyl)]-
T1~ PO~Na2
propylphosphonic acid dzsodium salt
60
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Phospnonate derivative
l~Iame Structure
3-[2-(1,2,3,4-Tetrahydroisoquinoliny!)]-1-
propancphosphonic acid, disodium salt I ~ Nip ONa~
Propylphosphonic acid CH3CfiZCHiPO~Hz
Frthylphosphonic acid CHsCH2PO~Hi
Mcthylphosphonic acid CH3P03H2
tert-Butylphosphonic acid (CHl)3CPO3HZ
Phenylphosphonic acid
/ ~ POyHi
3-Aminopropylphosphonic acid NHic~-I1CH2CH2PO~Hz
(1-Aminopropyl)phosphonic acid NHZ
CH3CHzCH-P03HZ
Diethyl phosphoramidate o
H2N-P-(OCHICH3h.~
3-Aminopropy!(methyt)phosphinic acid, O
hydrochloride HIND P-OH HCl
Mc
4-Amino-1-butylphosphonic acid, O
~'isodiucn salt ~~t'(ONa~
HiN
61
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
1-(3-Phosphonopropyl)-benzimidazolc, O
disodium salt CH2CH2CH2P(ONah
~N
w N
3-Dimethylamino-1-propylphosphonic O
acid, disodium salt Me=NCfiiCHzCHiP(ONah
Diphenylamine-4-phosphoric acid,
disodium salt ~ / NH ~ ~ P(ONah~
3-Amino-butylphosphonic acid, ~P03Na2
disodium salt
NH=
3-Amino-pentylghosphonic acid, ~POsN$x
disodium sal - 't
NH1
3-Amino-hexylphosphonic acid, ~~:
disodium salt
NHS
3-Amino-hcptylphosphonic acid, ~1'Ia2
disodium salt
~x
3-Amino-octylphophonic acid, ~t'~ai
disodium salt
~z
3-Amino-4-methyl-pentylphosphonic acid,
disodium salt
~:
G2
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
3-Amino-3-methyl-butylphosphonic acid, ~PO~Nai
disodium sal -~ ''t
NH2
3-Amino-3-phenyl-propylphosphonic -
\ / ~sNaZ
acid,
z
disodium salt NH
3-Aniino~-phenyl-butylphosphonic acid, -
disodium salt . \ / Po~Na2
NHi
3-Amino-4-phenyl-pentylphosphonic acid,
disodium salt ~ POsNa~
w1
3-Amino-3-phenyl-butylphosphonic acid,
disodium salt
P03Na2
~:
2-Amino-2-(2-phosphonocthyl)-I,3,4- NH=
trihydronaphthalenc, disodium salt i ~ p
1-Amino-1-(2-phosphonoethyl)-
cyclohexanc, disodium salt
POsNaZ
2-(2-Amino-4- ~
phosphonobutoxy)tetrahydropyran PO~Nai
~o
NHx
63
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99101473
3-Amino-4-hydroxy-butylphosphonic HO~yNai
acid, NHi
disodium salt
3-Phasphonopropanesulfonic acid, o
trisodium Salt (NaOy~P~SOsNa
Diethyl 2-pyrrolidinylphosphonate
P(~Hsh
O
H
2-pyrrolidinylphosphonic acid, disodium
salt ~.P(ONah
O
H
1,1-Dioxo-2-(3-phosphonopropyl)- ~ ~p(oNah
isothiazoline, disodium salt N
os, o 0
2-Deoxy-2-phosphonoacetylamino-D- H
glucose o
OH OH
O
HO ~~~P(ONa}~
3-Hydroxy-3-(2-pyridyl)propcnyl-2- ~ ~ OH
phosphonic acid, disodium salt
~N
r(oNah
0
64
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 ~PCT/IB99/01473
3-Hydroxy-3-(3-pyridyl)propenyl-2-
phosphoric acid, disodium salt N , ~ off
P(ONah
0
3-Hydroxy-3-(4-pyridyl)propenyl-2-
phosphoric acid, disodium salt ~ ~ off
~P(oNa}i
O
3-Amino-3-(2-pyridyl)propenyl-2-
phosphoric acid, disodium salt , ~ NHi
N
P(ONayi
a
O
3-Amino-3-(3-pyridyl)propenyl-2-
phosphoric acid, disodium salt N ~ ~ NHi
~p(ortah
0
3-Amino-3-(4-pyridyl)propenyl-2- .'
phosphoric acrd; disodium salt '~ i NH=
P(ONa}~
O
65
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 .PCT/IB99101473
1,4-Diamino- I -(3-pyridyl)butyl-2-
phosphonic acid, disodium salt N
POzNaz
~z
1,4-D iamino-4-methyl-1-{3-
pyridyl)pentyl-2-phosphoric acid, ~ w ~NH2
disodium salt N i
P03Nai
NH=
1,4-Diamino-4-methyl-I-(2-
pyridyl)pentyl-2-phosphoric acid, ' w 'NHz
disodium salt
N~ PO~Nai
~x
1,4-Diamino-4-methyl-1-(4-
pyridyl)pentyl-2-phosphoric acid, w NHI
disodium salt ~ i
P~~x
NHS
3-(2-Amino-4,5,7,8-tetrahydro-6H
thiazolo[4,5-d]azepin-6-yl)propyl- HZN--~~N~N~P(~a~
phosphoric acid, disodium sal ~/t
3-[6-Methoxy-2-(1,2,3,4-tetrahydro- Meo
iso uinolin 1 ro yl hos honic acid,
q Y )~P P P P ~ ~ N~PO~Na~
disodium salt
66
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/0I473
3-[8-Methoxy-2-( 1,2, 3,4-tetrahydro
isoquinolinyl)]propylphosphonic acid,
disodium salt ~ ~~P~~Nai
OMe
2-(3-Phosphonopropyl)-I,2,3,4-
tetrahydro-9H pyrido[3,4-b]indole, ~ I (
disodium salt ~ N N~ PO~Na=
H
67
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
Pliosphono Carbohydrates
I~Iame Structure
2-Deoxy-2-phosphonoacet~rlamino-v- H
O
glucose OH OH
HO
NHCOCH~P(ONah
2-Deoxy-2-thiophosphonoacet7~lamino-o- H
O
glucose OH OH
HO
NHGOCHZP(ONa}i
~3-D-Glucopyranosylmethylphosphonic OH
Hp O CHiP(ONay~
acid, disodium salt O
H HO
a-D-Glucopyranosylmethylphosphonic OH
acid, disodium salt O
O
HO CH~P(ONah
6-Deoxy-6-C-phosphonomethyl-~- O
glucono- 8-lactone, disodium salt CHzP(ONah
HO O
H HO ~O
68
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 ~PCT/IB99/01473
6-Deoxy-6-C-phosphonomethyl-D- O
glucose, disodium salt cHzP(ONah
H p~~~
H HO OH
4-Deoxy-~-C-phosphonomethyl-O- off
glucose, disodium salt O
(Na0}~PH~ O
HO HO OH
3-Deoxy-3-C-phosphonomethyl-D- OH
glucose, disodium salt O
(NaOh H~ HO OH
O
1-Deoxy-N phosphonoacetylnojirimycin, OH O O
disodium salt N'OCHZp(O~h
HH ~.
HO
(I,5-Didwxy-I,S-imino-a.-~- OH H
glucopyranosyl)methylphosphonic acid, N'
disodium salt H O
Ho cHiitor~ah
1,6-Dideoxy-6-C-phosphonomethyl- 0
nojirimycin, disodium salt
~H
HO~'"'
HO
69
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 . PCT/IB99/01473
Tliiophosphona~e Derivatives
hIame Structure
'Ihiophosphonoformic acid, trisodium salt 'I
NaO~ p~ ONa
ONa
O
Thiophosphonoacetic acid O S
~'p~ OH
HO OH
Thiophosphonoacetic acid, trisodium salt O
~P~ ONa
Na0 ONa
Thiophosphonoacetic acid, triethyl ester O
p\ OEt
Ec0
Chloro(thiophosphono)acetic acid, O
gyp' oNa
trisodium salt
Nao a oNa
Dichloro(thiophosphono)acetic acid,
o ~p-orta
trisodium salt
Na0
a a
~a
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 .PCT/IB99/01473
Thiophosphonomethylthiophosphonic ~I (I
acid, tetrasodium salt
NaO~% ~ \ ONa
Na0 ONa
Phenylthiophosphinomethylthio- s S
phosphonic acid, trisodium salt
Ph''~/P~IP\ ONa
Na0 ONa
3-[2-(1,2,3,4 Tetrahydroisoquinolinyl)]-1-
propanethiophosphonic acid, disodium f ~ N~'p(p~h
salt
propylthiophosphonic acid
(~I3a32a~:PO=H2
Ethylthiophosphonic acid
a-13CHZP0=HZ
Methylthiophosphonic acid S
a ~hP01H2
terl-Butylthiophosphonic acid
~~3~3~H2
2-Carboxyethylthiophosphonic acid
HO=OCH2ai2P0=H:
Phcnylthiophosphonic acid
/ \ ~POiH?
3-pminopropylthiophosphonic acid
NHia~iCH=CH2P(OHh
(d~-2-Amino-3-thiophosphonopropionic NHZ s
acid Ho=o~a;~P(oHh
!t-Aminopropyl)thiophosphonic acid NHi S
CH~atiCi~i_ P(OHh
71
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
(d~-2-Amino-5-thiopf~osprtonopentanoic ~ S
acid
HO~OCHCHZCHiCHZP(OEi~
(,S~-2-Amino-2-methyl-4- S
thiophosphonobutanoic acid Hpi P(OHh
Hi
v-2-Amino-4-thiophosphonobutanoic acid ~H
H..~. ~S
HZN~ F(OHh
L-2-Amino-4-thiophosphonobutanoic acid H
H2N,,~S
H ~P(OHh
D-2-Amino-7-thiophosphonoheptanoic H S
acid H'~.~ ~p(D~
HEN
L-2-Amino-?-thiophosphonohcptanoic ~H S
acid HxN"~ ~P(OH~
H
D-2-Amino-6-thiophosphonohexanoic acid ~H
H...
H2N P(D~
L-2-Amino-6-thiophosphonohexanoic acid
H=ls...
H P(OHyi
o-2-Amino-4-thiophosphonopentanoic H S
acid H ~~~p(Ot~
HZN
~-2-Amino-4-thiophosphonopentanoic H S
acid H2N'~~~p(p~
H
o-2-Amino-3-thiophosphonopropionic ~1; S
acid H.~,P(O~
H=N
72
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 ~PCT/IB99/01473
~_2-Acnino-3-thiophosphonopropionic CpIH S
acid HzN.~P(oHy~
H
3-Aminopropyl(methyl)thiophosphinic s
acid, hydrochloride H2N~ P-OH ~ HCI
Me
(R)_3-(z_~rboxypiperazia-4-yl)-propyl-
1-thiophosphonic acid
H
~H .
t,-4-[Di~luoro(thiophosphono)methyl)]- O _
phenylalanine ~ ~ CFiP(OHh
HO
NH=
(~~-(3 Thiophosphonoprop-2-
enyl)piperazine-2-carboxylic acid
H
OpiH
traps-~-4 ~oPhosphonomethylproline, NaOiC H
trisodium salt
S
cH=p(or~a~1
c~_L~ Thiophosphonomethylproline, Na0=
trisodium salt N s
CHiP(ONah
4-Amino-1-butylthiophosphonic acid,
disodium salt ~P(ONah
H=T~I
73
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PCT/IB99/01473
1 _(3-'fhiophosphonopropyl)-
imidazole, disodium salt CH=CHzCH P~(ONa}~
bent N
3-Dimethylamino-1-propylthiophosphonic
acid, disodium salt MeiNCH2CHZCHiP(ONah
N,N Diethylthiophosphonoacetamide, O
IP~ ONa
disodium salt ~~
E~ rr
ONa
Diphenylamine~-thiophosphonic acid, _
disodium salt NH ~ ~ P(oNah
Selenophosphonoformic acid, trisodium
salt Na0 P~ ONa
ONa
O
Sclcnophosphonoacctic acid, trisodium O''
J!"p\ ONa
salt
Na0/ ~ ONa
D-2-pinino-3-selenophosphonopropanoic
acid H N~~p(Ot~
i
~ 2_pLnino-3-selenophosphonopropanoic ppiH sc
H21~~~P(OH}~
acid
H
o-2-Amino-4-sclenophosphonobutanoic CO=H
P(OH}~
acid H N
~-2-Amino-4-selenophosphonobutanoic HZ~ O~H
acid H~~~O~
74
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 PC'f/IB99/OI473
N Cyclohexylthiophosphonoacetamide, O
~~P~ ONa
disodium salt
~ ONa
N Cyclohexyiselenophosphonoacctamide, o
~P~ ONa
disodium salt
o- H ONa
N Hydroxythiophosphonoacctamide, o
~,p~ ONa
disodium salt
!-tONH ONa
Thiophosphonoacetic hydrazade, disodium O
salt ~'P~ ONa
ONa
IV Thiophosphonoacetyl-~-alanine, ~I O o00Na
Na0-P
trisodium salt
Na0
rl Thiophosphorioacetyl-t,-glyeine, i' o
Na0-~P~
trisodium salt
~~ZOpONa
Na0
N-(Thiophosphonoactyl)-L-asparagine-t.- i' o :~~z
NaO~-~P~~ '~ ~~a~Na
glycine, tetrasodium salt
'O O
(s)-2-Pyrrolidinemethylthiophosphonic H
acid, disodium salt
N H 'P(ONa}i
'w./
75
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 ~ PCT/IB99/01473
I,1-Dioxo-2-(3-thiophosphonopropyt)- ~./~ ONa
isothiazolidine, disodium salt
00
2-Deoxy-2-thiophosphonoacetylamino-D- HO
glucose O
OH OH
S
HO
3-(2-Amino-4,5,7,8-tetrahydro-6H
thiazolo[4,5-djazepin-6-yl)propyl- H2N--~,N ~ ~'~~P(ONah
thiophosphonic acid, disodium salt
76
SUBSTITUTE SHEET (RULE 26)
CA 02338705 2001-O1-26
WO 00/06133 ~ PCT/IB99/01473
t ,1-D ioxo-2-(3-thiophosphonopropyi)-
isothiazolidine, disodium salt ~N~S oNa
pS, O
2-Deoxy-2-thiophosphonoacetylamino-D- Hp
glucose p
OH OH
HO
NHQOQi~P(ONah
3-(2-Amino-4,5,7,8-tctrahydro-6H
thiazolo[4,5-djazepin-6-yI)propyl- H=N..-~S ( r, S ONa
thiophosphonic acid, disodium salt N t~~ )z
77
SUBSTITUTE SHEET (RULE 26)
